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Preface
Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant disorders with a
high propensity to develop acute myeloid leukemia (AML). While the prevalence of MDS is
approximately equal to that of AML, the biological aspects of MDS are not as well
understood as in AML. This is partly due to the fact that a large portion of MDS patients
consists of elderly people with an indolent disease type, which does not require medical
intervention. Other reasons why biological understanding of MDS lags behind that of AML is
that subgroups in MDS are more difficult to classify based on morphology alone, and by the
nature of the chromosomal aberrations found in the two diseases. Specific translocations
present in AML, led directly to further investigation of the genes involved. However, the
large numeral aberrations in MDS such as monosomy of chromosomes 5 or 7 and trisomy of
chromosome 8 have not provided such orientation points. Even the deletion of the 5q region
in MDS may affect different genes in different patients, as no single, minimal deleted region
could be identified.
This thesis describes molecular biological studies on MDS: the study of clonality with
cytogenetics, FISH and determination of X-chromosome inactivation patterns (XCIP), and the
determination of expression patterns of single genes, including some technical improvements
for these techniques. The introduction contains a strong plea for the application of new
techniques in MDS research, such as expression-based micro-arrays. In order to fine-tune
therapy, come to a better, more prognostic classification of MDS and a better monitoring of
treatment efficiency a better understanding of MDS biology is essential. Identification of
MDS specific mutations may ultimately lead to therapies specific for those mutations.
8 J.P. van Dijk
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Introduction
Part 1
Monitoring treatment efficiency in MDS at the molecular level; possibilities
now and in the future.
General characteristics of MDS
Myelodysplastic syndromes (MDS) are a heterogeneous group of disorders affecting the
normal differentiation of hematopoietic cells. Clinical manifestations of MDS overlap with
aplastic anemia (AA), myeloproliferative syndromes (MPS) and acute myeloid leukemia
(AML). All types of MDS share morphologic dysplastic features in the myeloid,
megakaryocytic, and/or erythroid development, frequently resulting in cytopenias of the
affected lineages. The percentage of blasts in the bone marrow (BM) ranges from normal
percentages (1-5 %) to 20% in the World Health Organization classification1 or to 30% in the
French American British (FAB) classification.2 The course of the disease varies from an
indolent type of disease that remains stable for many years to an aggressive type with rapid
progression to AML, or death due to severe multi-lineage cytopenias. The international
prognostic scoring system (IPSS) is a helpful tool to predict disease outcome.3,4 This system
is based on the number of cytopenias, the percentage of BM blasts, and the type of
cytogenetic aberrations (Table 1). This system provides improved prognostic strength
compared to the FAB classification, which is mainly based on the blast percentage in blood
and BM and the BM morphology. The IPSS study underlying this score divided a cohort of
816 primary, untreated MDS patients into four risk groups: low-risk, intermediate (INT)-1,
intermediate-2 and high-risk group. Patients with FAB type RA (refractory anemia) could be
separated into low-risk, INT-1 and INT-2; those with RARS (RA with ringsideroblasts) into
low-risk and INT-1. Patients with the FAB type RAEB (RA with excess of blasts) were
mainly grouped in the INT-2 group with a small percentage in the INT-1 group. Patients with
the FAB type RAEB-t (RAEB in transformation) fell into INT-1, INT-2 and high-risk groups.
Patients with the FAB type CMML (chronic myelomonocytic leukemia) were present in all
risk groups. The IPSS has been proven a reliable tool to predict both survival and evolution of
MDS patients to AML. Patients in the high-risk group have a typical survival time of less than
one year, while the median survival time for patients in the low-risk group was between 5 and
6 years in the initial IPSS study.
The incidence of newly diagnosed patients with MDS is approximately 2.8 per 100,000
inhabitants annually in the USA. Various European studies show an incidence of 2.1 to 4.1
cases per 100,000 inhabitants per year, which is comparable with or even higher than the
incidence of AML (reviewed by Aul et al5). MDS is a condition that mainly affects people
from middle age onwards although this disease is also recognized at juvenile ages.
Documented exogenous risk factors for MDS include benzene exposure and previous
treatment with alkylating or other cytotoxic agents (reviewed by Aul et al6).
Treatment of MDS
Treatment of MDS is as diverse as its clinical manifestations. For elderly and low risk patients
supportive treatment is most common, consisting of transfusions with erythrocytes and/or
platelets. Alternative therapies include treatment with growth factors (erythropoietin, G-CSF
and GM-CSF), differentiation inducing agents and low-dose chemotherapy (reviewed by
Asano and Niho7). The only accepted curative treatment for MDS is allogeneic stem cell
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Table 1a International Prognostic Scoring System (IPSS) for Myelodysplastic Syndromes
(MDS)3
Score value
Prognostic variable 0 0.5 1.0 1.5 2.0
BM blasts (%) <5 5-10 - 11-20 21-30
Karyotypea Good Intermediate Poor
Cytopenias 0/1 2/3
a Good, normal, -Y, del(5q), del(20q); Poor, complex (≥3 abnormalities) or chromosome 7 anomalies;
Intermediate, other abnormalities.
Table 1b Survival and Evolution to Acute Myeloid Leukemia (AML)3
Riskgroup Score AML Survival
Low risk 0 > 18 yrs 65 months
Intermediate I 0.5 – 1.0 8 yrs 40 months
Intermediate II 1.5 – 2.0 36 months 14 months
High risk > 2.5 6 months 5 months
Scores for risk groups are as follows: Low, 0; INT-1, 0.5-1.0; INT-2, 1.5-2.0; and High, ≥2.5
transplantation (alloSCT) alone or in combination with high-dose chemotherapy to obtain a
remission status before transplantation.8-11 Various studies showed a 4-year survival between
20 and 30% for high-risk patients. This treatment is available to only a limited number of
patients because of the lack of suitable donors and the intensity of the procedure, which is in
many cases incompatible with the age of the patient. As an alternative, autologous stem cell
transplantation (ASCT) as an intensive consolidation therapy is currently being investigated
for its curative potential.12
Clonality in MDS at diagnosis
MDS is considered a clonal hematopoietic stem cell disorder. Clonality has been investigated
at three different levels. The first level comprises large chromosomal aberrations. Such
aberrations are observed in approximately half of the patients. The most frequent
chromosomal anomalies are monosomy of chromosme 7 (-7), trisomy of chromosome 8 (+8)
and deletion of 5q (5q-). MDS evolving after chemotherapy (treatment-related MDS or t-
MDS) has a higher prevalence of aberrations up to 80% of cases.13 Deletions or loss of
chromosomes 5 and 7 are associated with previous therapy with alkylating agents and
balanced translocations to chromosome bands 3q26, 11q23 and 21q22 are associated with
exposure to drugs targeting DNA-topoisomerase II.14 Aberrations are routinely detected with
standard banding karyotyping. This technique involves stimulation of cell division to obtain
metaphases, potentially leading to an altered ratio of malignant and normal cells in a sample.
Therefore it cannot be used to reliably quantify the percentage of clonal cells in a patient
sample. Fluorescent In Situ Hybridization (FISH) can be carried out on interphase cells. Like
karyotyping, FISH can be used to detect large chromosomal aberrations and does so by
hybridization of fluorescent probes specific for the chromosomes involved. With FISH the
percentage of malignant cells in a sample can be quantified, assuming that the aberration is
specific (no background in normal cells) and that all malignant cells carry the aberration (first
or early hit in pathogenesis of the malignant clone).
The second level to investigate clonal relations in cell populations is the determination of the
X-chromosome inactivation pattern (XCIP) in the cells of female patients. X-chromosome
inactivation, also known as Lyonization, occurs early in embryogenesis and involves the
random inactivation and methylation of either of the two X-chromosomes in all female
cells.15 Once established, XCIP of a particular cell will be transferred to all the progeny of
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this cell. As a result a normal cell population of a healthy female usually shows a 50:50 ratio
of inactivated paternal and inactivated maternal X-chromosome alleles. The percentage of
clonal cells in a sample can be calculated from the XCIP ratio. XCIP determination is less
sensitive than FISH. A cell population is considered clonal when the XCIP ratio is more
extreme than 75:25. This means that a cell population has to harbor more than 50% of clonal
cells to be considered clonal with this technique. The margin of error of XCIP determination
with PCR based techniques is 10%.16
The third level to investigate clonality is the detection of point mutations. Point mutations
such as observed in the ras gene can be detected by PCR amplification of the affected ras
gene codons, followed by hybridization with a mutation specific labeled probe. Halfway the
1990s it became clear that in the majority of patients, the myeloid and erythroid cells are
predominantly derived from the malignant clone (reviewed by Weimar et al17). With all these
techniques clonality had also been observed in lymphoid cells in a minority of patients,
although contamination of lymphoid cell populations with myeloid cells may have influenced
the outcome of these observations.
Since then, FISH in combination with purification of cell populations using flow cytometric
sorting based on the expression of CD (cluster of differentiation) markers has shed more light
on the types of cells involved in MDS (Table 2).18-24 While such studies all confirmed
clonality of erythroid and myeloid lineages, results on lymphoid and progenitor cells were
variable between studies. Concerning T cells (CD3+), only one positive case has been
identified.19 This was an RA patient with +8. Of the CD3+ cells, 72% showed the aberration,
as did 62% of the primitive progenitor cells (CD34+, lineage negative) in this patient. In other
studies T cells were always negative for the cytogenetic aberration in the 25 patients
studied.18,20-23 For B cells (CD19+), 3 patients showed aberrant chromosomes18,20,23, while B
cells of 23 patients were negative for the MDS specific aberration.18,20-23 Interestingly, the B
lymphoid progenitor cells seem to belong to the MDS clone more often.22 In one study 3 out
of 3 patients showed aberrant B cell progenitors (CD34+, CD19+), with respectively 94, 67
and 25% of aberrant cells. Mature B cells were only positive for the aberration (5q-) in the
patient with the highest percentage of aberrant progenitors, albeit to a lesser extent (32%).
Natural Killer (NK) cells (CD3 negative, CD56+) were negative for the MDS aberration in 8
patients,20,21 and aberrant NK cells were observed in 3 patients with -7.21 In the first two
cases also the T/NK common progenitor cells (CD34+, CD7+) were investigated. The T/NK
progenitors showed the aberration in respectively 96 and 21% of cells. Several groups
investigated other progenitor cell subpopulations. Myeloid progenitors were invariably found
to contain at least 90% aberrant cells. When a population enriched for hematopoietic stem
cells (CD34+Thy1+) was compared with more committed progenitor cells (CD34+Thy1
negative) for the presence of +8, the aberration was only found in the more committed
progenitors in all four cases.20 However, in another study by the same group, CD34+Thy1+
cells were found to contain 98% of cells with -7.21 When another population enriched for
primitive progenitors or hematopoietic stem cells (CD34+, CD38 negative) was investigated,
high percentages of cells with 5q- were found in all 9 patients.22 Furthermore, when +8 and
5q- were assesed simultaneously in primitive and committed progenitors, +8 was only
detected in cells that also showed 5q-.24 Deletion of 5q did occur as single aberration. In the
same study, four patients showed similar results in overall BM samples. Trisomy 8 was only
detectable in cells that also contained 5q-, but 5q- did occur in cells without +8. This implies
that +8 is a later event in the multistep pathogenesis of MDS. This also implies that
hematopoietic stem cells in patients with +8 as a single anomaly may be affected by the MDS
clone even if these cells do not show the (secondary) aberration. The same study substantiated
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this hypothesis. When primitive (CD34+, Thy1+) BM cells from a patient with trisomy 8, with
a considerable amount of cells disomic for chromosome 8, were transplanted to NOD-SCID
mice, normal human hematopoietic stem cell capacity was defective in these mice, indicating
the dysplastic nature of the transplanted cells.
Taken together, results from the combination of FISH with flow cytometry have strengthened
the notion that MDS arises in a hematopoietic stem cell, the progeny of which maintains the
ability for (dysplastic) myeloid and erythroid maturation but is severely restrained in
maturation into other lineages, especially T cells. This notion is further strengthened by the
finding that transformation of MDS to acute lymphoblastic leukemia does occur, but as a very
rare event.25
Techniques using XCIP revealed clonality in the myeloid cells of MDS patients also when
large chromosomal abnormalities were absent (reviewed by Weimar et al17). Although initial
studies revealed T cells with a non-random XCIP, later studies on healthy female donors
revealed that clonal patterns also occur in both myeloid and lymphoid cells in normal, healthy
individuals. The prevalence of non-random XCIPs in hematopoietic cells of healthy females
increases with age, a process called acquired skewing of Lyonization (Table 3).26-33 On
average, skewing of XCIP in hematopoietic lineages varies from 22% early in life to 42% of
elderly females, though studies in neonates and cord blood samples show discordant results.
Skewing of XCIP in elderly females may be as high as 56% in granulocytes and as low as
17% in T cells. Acquired skewing of T cells lags somewhat behind that of myeloid cells,
leading to a typical myelo-clonal pattern in a number of healthy individuals (‘clonal’ myeloid
cells with ‘polyclonal’ T cells).33-35 This means that in individuals or small groups of elderly
patients with myeloid disorders as MDS and MPS clonality cannot be distinguished from
acquired skewing of XCIP. Abkowitz et al. was the first to show that acquired skewing is
likely to be caused by a polymorphic gene on the X-chromosome in cats.36 Later studies in
healthy elderly female twins have confirmed this in humans.34,37 In both studies a strong
correlation existed between the twins with regard to the allele in which direction the skewing
occurred and the degree of skewing. Results from a recently published study suggest that T
cells may be clonal after all in some patients, especially in low-risk MDS when compared to
high-risk MDS.38
While most experts agree about the general clonal involvement of myeloid cells in MDS, not
all myeloid cells in MDS are clonally related in all patients.39-42 It is clear that in a substantial
percentage of MDS patients residual normal myelopoiesis is still present besides the
malignant clone.43 However, the degree of (poly-) clonality and its impact on survival of
MDS patients is not fully understood. We found no difference in survival between high risk
MDS patient with clonal or non-clonal myelopoiesis at diagnosis when treated with high dose
chemotherapy, although the number of patients with non-clonal myelopoiesis was small (this
thesis, Chapter 3).
Clonality in MDS in complete remission
Although high dose chemotherapy leads to complete remission rates of up to 60%, relapse
rates are generally high, leading to overall survival rates of about 20% (reviewed by Asano &
Niho 7). Several groups have studied the treatment efficacy at the molecular level.44-50
Various studies have shown that polyclonal as well as cytogenetically normal remissions can
be achieved in MDS after various treatments (Table 4). Indeed, we found a trend towards
better survival for patients with a cytogenetically normal remission compared to those with
Introduction, Part1
Molecular studies in MDS 13
Table 2 FISH analysis on sorted lymphoid and progenitor cells in MDS patientsa
BM progenitors
prim OP committed
mature PB cells
MDS
type
anomaly
analyzed OC BP T/NK B NK T ref.
RAEBt -7 +++ ++ - 18b
RA -7 +++ - -
RA -7 +++ - -
RAEBt +8 ++ ++ 19
CMML +8 - +++ - - - 20
RAEB +8 - +++ - - -
RAEB +8 - +++ - - -
RAEBt +8 - +++ - - -
RA +8 - - -
RA +8 - - -
RA +8 - - -
RA -7 +++c - +++ - ++ - 21
CMML -7 -c ++ -
RA -7 + - + -
RAEBt -7 - - -
RA 5q- +++ +++ - - 22
RA 5q- ++ -c -
RA 5q- +++ +++ - -
RA 5q- +++ +++ +++ + -
RA 5q- +++ - -
RAEB 5q- +++ +++ - -
RA 5q- +++ +++
RA 5q- +++ +++
RA 5q- + - -
RAEB 5q- +++ +++
RAEB 5q- +++ +++ - -
RAEB 5q- +++ +++ - -
RA 5q- -c - 23
RA 5q- - -
RA 5q- + -
RAEB 5q- alone + ++ 24
+8 alone - -
5q- and +8 ++ +
positive/total number
of patients (%)
12/16
(75)
4/4
(100)
14/14
(100)
3/5
(60)
2/2
(100)
3/26
(12)
3/11
(27)
1/26
(4)
BM: bone marrow, PB: peripheral blood, prim: primitive; CD34+, lineage- in 19; CD34+, Thy1+ in 20,21
and CD34+, CD38- in 22,24, OP: overall progenitor; CD34+, OC: overall committed: CD34+, Thy1- in
20,21 and CD34+, CD38+ in 22,24, BP: B cell progenitor; CD34+, CD19+, T/NK: T/NK cell progenitor;
CD34+, CD7+, B: B cell: CD19+, NK cell; CD3-, CD56+, T: T cell; CD3+
a In most studies, also myeloid cells and/or myeloid progenitors were evaluated, these were always
positive for the chromosomal aberration. In all cases 100 cells or more were counted unless otherwise
indicated. +++: ≥90% positive cells, ++: between 50 and 90% positive cells, +: between 10 and 50%
positive cells, -: <10% positive cells.
b between 40 and 400 cells were counted
c between 50 and 90 cells were counted
persisting abnormalities (p = 0.087, this thesis, Chapter 3). Furthermore, the relapse incidence
was lower in the former group (57%) than in the latter group (93%, p = 0.015). Nevertheless,
the achievement of a cytogenetic remission is no guarantee for disease-free survival. Patients
in cytogenetic remission who eventually relapse will harbor residual disease in primitive BM
populations not detected by cytogenetic techniques on overall cell populations. Confirming
this, Engel et al. showed that only one out of 12 MDS patients who achieved complete
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Table 3 Incidence of acquired skewing of XCIP (more extreme than 25:75) in total white
blood cells (WBC), granulocytes (gran) and T cells of healthy female donors.
A B C ref
age < one year intermediatea elderly
p-value
A vs. C
p-value
B vs. C
WBC 14/162 (8.6%) 11/67 (16%) 25/66 (38%)b 0.0064 <0.0001 26
gran 26/65 (40%)c 27
T cells 11/65 (17%)c 27
WBC 21/94 (22%) 28
gran 6/23 (26%) 45/80 (56%)d <0.0001 28
T cells 32/80 (40%)d 28
WBC 3/36 (8.3%) 5/30 (17%) 14/31 (44%)d 0.0006 0.02 29
WBC 0/46 (0%) 6/29 (21%)e 30
WBC 34/121 (28%)g 67/139 (48%)b,g <0.001 31
gran 6/29 (21%) 6/14 (43%)f 0.029 32
T cells 0/29 (0%) 3/14 (21%)f 32
gran 4/20 (20%) 6/15 (40%)a 0.04 33
total
WBC 17/198 (8.6%) 71/312 (22%) 112/265 (42%)
gran 6/23 (26%) 10/49 (20%) 83/174 (48%)
T cells 0/29 (0%) 46/159 (29%)
a Various age groups were investigated in the intermediate group, varying between studies from 17 to
65 years, b > 60 years, c > 63 years, d > 75 years, e > 50 years, f > 65 years, g both healthy female
donors and patients with non-hematological malignancies were investigated.
remission (CR) after chemotherapy was in cytogenetic remission when progenitor cells were
investigated with FISH49 and 4 out of 13 patients in another study.46 Interestingly, the authors
found that in 2 cases residual abnormal cells could only be detected after sorting CD34+ cells
and that in the other patients the load of abnormal cells in the sorted BM progenitor cells was
two- to threefold higher than in the unfractionated BM.
The major advantage of XCIP based clonality assessment is the relation of this type of
analysis with the first hit in the clonal evolution of MDS. A second advantage is that about
90% of (female) patients can be investigated, irrespective of cytogenetic abnormalities and
other prognostic factors. However, acquired skewing of Lyonization may mask a treatment
response in patients who still show clonality in CR. As the margin of error for the XCIP as
determined by HUMARA PCR is approximately 10%,16 a fully balanced XCIP at CR may
still harbor 20% clonal cells, indicating a lower detection sensitivity with XCIP determination
than with cytogenetic analysis (~10%). Both the low sensitivity of the technique and the
presence of biological skewing of XCIP resulted in an absence of predictive value of clonality
in CR (p = 0.91, this thesis, Chapter 3).
An alternative way for assessing the response to treatment and a possible indication for
survival might be monitoring of specific mutations with quantitative PCR. However, until
now no generally occurring or specific point mutations have been identified in MDS.
Although mutations in the Ras gene family are fairly common in MDS (reviewed by
Fenaux51), these may not be useful for monitoring of treatment success as they have been
shown to disappear after progression to AML in some cases52 and to appear as second hit
mutations in other cases.53
Future directions
Two decades of molecular research have not established a common biological cause for MDS,
but a number of frequently occurring abnormalities have been documented (reviewed by
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Fenaux51). Of these, only large chromosomal aberrations have been incorporated in
prognostic scoring systems for MDS patients. The identification of distinct biological
pathways in MDS will serve two purposes. First, gene expression profiling may result in a
better classification of MDS patients and a better discrimination from diseases with similar
clinical manifestations, such as aplastic anemia and MPS. The development of cDNA micro-
arrays that allow the simultaneous analysis of expression of several thousands of
(hematological) genes is very likely to provide a better MDS classification or at least a fine-
tuning of the existing classifications. This is clearly needed, as the present classifications are
predictive for survival, but patients within the same risk group still react differently to various
treatment forms. The first step in this direction has already been taken with studies in
transcription pathways involved in proliferation and differentiation in MDS54 and in genes
with MDS specific expression patterns.55 Secondly, a better insight in abnormal gene
expression or disease specific mutations or translocations may provide new targets for
monitoring of residual disease after treatment. This need is also apparent: current treatments
include consolidation treatment after achievement of CR by high-dose chemotherapy.
Monitoring of residual disease at this stage may identify patients who may be excluded from
intensive antileukemic treatment either because they do not need it or because they will not
benefit from it. In the latter case, patients may be offered experimental treatment or palliative
treatment. Ideally, a target for residual disease monitoring would be a mutation or
translocation by a tailor-made quantitative real-time (RT-) PCR method. Such methods have
proved useful in predicting relapses for patients with several types of leukemic translocations,
including t(8;21), inv16 (reviewed by Liu Yin56) and t(15;17) (reviewed by Grimwade57) in
AML and t(14;18) in ALL (reviewed by Kaeda et al.58). Unlike arrays containing the whole
human genome, expression based micro-array analyses are not expected to provide such
targets directly. However, they do provide the genes or genetic pathways that should be
investigated for mutations or translocations. Alternatively, aberrant expression of a particular
gene may serve as a marker for residual disease, such as is currently being investigated for the
WT1 gene in AML (reviewed by Liu Yin56). A major drawback for this method is the
background expression of the so-called leukemia specific genes, in normal cell populations.
For instance, while the expression of the WT1 gene in leukemic BM was initially considered
to be specific for leukemic cells59, later studies using more sensitive methods showed WT1
expression in healthy BM as well, albeit at a lower level.60 Subpopulations of healthy BM
cells were even shown to express WT1 at similar levels as leukemic cells.61-63 No consensus
has been reached yet on the WT1 expression level in normal BM. MRD monitoring based on
aberrant gene expression should be treated with caution and may never be as precise as
monitoring of specific mutations or translocations. Noteworthy, background gene expression
occurs in the healthy population but also the occurrence of leukemia specific translocations
has been described in healthy individuals, though at very low levels (reviewed by Basecke64).
As straightforward as the strategy outlined above might be, it will take a huge effort and
several years of research before micro-array studies may provide new profiles for
classifications and new targets for disease monitoring in MDS. In the meantime, it is
worthwhile to apply techniques that are common to most academic centers, such as the
combination of FISH and cell sorting, for monitoring of treatment outcome in large
(international) studies.
16 J.P.van Dijk
Table 4 Molecular analyses in complete remission
treatment analysis patients in CR molecular response reference
LDC XCIP 3 3 44
HDC XCIP 1 1 45
HDC FISH 13 4 46
HDC XCIP 6 2 47
LDC/Pall Karyotyping 13 8 48
HDC FISH 12 1 49
HDC XCIP 6 5a 50
HDC Karyotyping 46 32 b
HDC XCIP 21 12 b
LDC, low dose chemotherapy; HDC, high dose chemotherapy; Pall, palliative treatment. a only
analyses at CR. b this thesis, Chapter 3.
Conclusions
Most studies support the idea that MDS clones arise at the level of a pluripotent
hematopoietic stem cell. Mature lymphocytes are not affected in the majority of patients, but
MDS specific aberrations have been observed in almost all progenitor cell types, including
very primitive progenitors, and more mature myeloid and lymphoid progenitors. A minority
of patients has been identified in whom the majority of mature myeloid cells are polyclonal,
but the impact of this information remains to be elucidated. Curative options for MDS
patients are still limited, despite recent promising advances in chemotherapy and SCT
regimens. A major challenge is the development of alternative or supplemental treatments for
patients refractory to SCT or chemotherapy. Cytogenetic analysis at diagnosis as well as in
CR identifies patients who have a higher chance to benefit from antileukemic treatment. This
technique may be even more informative if assessed with FISH on primitive BM fractions.
The assessment of clonality with use of XCIP determination is problematic because of limited
sensitivity and the increased acquired skewing of XCIP in healthy elderly females.
A better understanding of MDS biology is essential in order to fine-tune therapy, to develop a
better prognostic classification of MDS and to monitor treatment efficiency more sensitively.
Identification of MDS specific mutations or translocations may ultimately lead to therapies
specific for those mutations as was the case for CML recently.65
Molecular studies in MDS 17
Part 2
WT1 expression in leukemia; facts and implications.
The WT1 gene has been implicated in the development of Wilms’ tumor, a pediatric kidney
cancer.66,67 The gene encodes a protein that acts as a transcription factor but it may also play a
role in posttranscriptional modification (for a recent review see Menke et al).68 Alternative
splicing results in four biologically distinct proteins.69,70 In various malignancies a role for
WT1 has been proposed, either through point mutations (Wilms’ tumor, leukemia71-74),
translocations (desmoplastic round cell tumor75), or aberrant expression (mesothelioma,
leukemia, breast carcinoma76-78). Mice with homozygous null mutations are non-viable, lack
kidneys, gonads and adrenal glands, and show defective formation of the heart and spleen.79-
81
 Recently, distinct functions were shown in mice for the splice variants with or without an
insertion of three amino acids (KTS) between the third and fourth zinc finger.82 Mice with
reduced levels or absence of either WT1 isoform presented with severe kidney defects.
In normal hematopoiesis WT1 expression occurs in primitive, CD34 positive BM blasts,
decreases during differentiation and is not detectable in mature blood cells.83,84 Mutations in
WT1 occur in approximately 10% of AML cases suggesting a role for WT1 in the
pathogenesis of leukemia.73,74 No WT1 mutations were found in 27 MDS cases, and in only
one out of 17 patients with AML after MDS a mutation was found.85
A high expression of WT1 in the bone marrow of patients with various types of acute
leukemia has been well established and reviewed.86,87 In AML a high WT1 expression was
shown in the overall BM of about 90% of patients. High WT1 expression was also observed
in acute lymphoblastic leukemia, chronic myeloid leukemia in blast crisis and in advanced
cases of MDS, such as refractory anemia with excess of blasts (RAEB) and RAEB in
transformation (RAEBt). In contrast with the consensus on WT1 expression in leukemia is the
debate on WT1 expression in normal, healthy bone marrow. All groups investigating WT1
expression in normal BM have found WT1 expression in subpopulations of normal BM cells
and leukemic BM cells. However, the level of expression in normal BM cells varied (Table
1). One study showed a ten-fold higher expression of WT1 in leukemic cells compared to
normal primitive BM cells.60 On the other hand, three other groups did not observe significant
differences in WT1 expression between malignant blasts and normal CD34+
progenitors.61,62,88 Interestingly, the group that observed a difference between WT1
expression in primitive leukemic and donor cells later identified cells in normal healthy BM
with expression of WT1 similar to that in the cell line K562, although the frequency of those
cells was low (1.2% of CD34+ cells).63 This may imply that the WT1 expression in leukemic
cells is not higher than the expression in their normal BM counterpart. This may also indicate
that the high expression of WT1 found in various types of leukemia and AML may result
from a lack of downregulation in more mature populations rather than an aberrant
overexpression.
The importance of WT1 downregulation for differentiation has been shown in several studies
(reviewed in89). In healthy BM, the level of WT1 expression drops beyond detection level
during differentiation.83,84 In the human leukemic cell lines HL 60 and U937 differentiation
induction can be completely or partially blocked by ectopic WT1 expression.90,91 In the K562
cell line different groups found either no effect or a delay in the inducible differentiation upon
WT1 overexpression.92,93 Ectopic WT1 expression caused a complete or partial
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differentiation block both in murine 32D cells and in murine primary BM cells.94,95 In the M1
murine leukemia cell line forced expression of WT1 induced differentiation.96 These cells
also showed a decrease in tumorigenicity when injected in C.B.-17 scid/scid mice.97
Retroviral transduction of primary human CD34+ cells with WT1 expression constructs
resulted in enhanced differentiation of more mature progenitors and an increase in primitive,
quiescent CD34+CD38- cells.98 Furthermore, aberrant WT1 expression within dysplastic cell
lineages has been described in MDS patients.62 The development of mouse models in which
the expression of WT1 can be inactivated or activated in specific cell lineages may be an
important approach to unravel the function of WT1 in hematopoiesis and its role in the
development of leukemia.
The fact that WT1 expression in leukemic cells is similar to the expression in (a subset of)
normal BM cells is a major drawback for two proposed clinical applications of WT1: minimal
residual disease (MRD) monitoring and the development of anti-WT1 vaccines for
antileukemic treatment. The MRD monitoring in leukemia patients after chemotherapy or BM
transplantation is a useful tool to predict treatment outcome and may be used as a parameter
for further treatment. The background WT1 expression in normal primitive BM cells makes
WT1 a doubtful target and certainly a less sensitive one for MRD monitoring than specific
translocations or mutations. On the other hand, the fact that high WT1 expression occurs in
~90% of AML cases, makes WT1 a virtually universal target for MRD monitoring. The
usefulness of WT1 for MRD monitoring is currently being investigated and may depend on
the method used and the investigated material (blood or BM).56
Immune-therapy for eradication of (residual) malignant cells is a promising stategy in
leukemias and solid tumors. Both vaccination with tumor specific peptides or proteins and
infusion of specific anti-tumor T cells are interesting approaches. Therapies target tumor
specific antigens. Most targets are fetal proteins that are rarely expressed in adult tissues
(MAGE-1 and HER-2/neu). Other targets are related to a differentiated protein function in the
malignant tissue (tyrosinase and gp100).99-101 The WT1 protein has been shown
immunogenic: immunization of mice with WT1 peptides induces WT1 specific T cell
responses and sera of leukemia patients were found to contain WT1 specific antibodies and T
cells, indicating a pre-existing anti-WT1 response (reviewed in102). However, antileukemic
immunotherapy targeting WT1 expressing cells could destroy all hematopoietic stem cells
and all other cells that normally express WT1.
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Table 1 WT1 RNA expression relative to β-actin expression, relative to WT1 in the leukemic
cell line K562 and in donors compared to AML/MDS patients.
method material (n) WT1/β-actin WT1
sample/K562
WT1
malignant/donor
ref.
single-round RT PCR donor CD34+ (2) 2.2 0.71 1.1 88
AML CD34+ (63) 2.3 0.74
nested RT PCR donor CD34+ (6) <1x10-2-2.4x10-2 >10 60
AML CD34+ (36) 2.4x10-1-9.3x10-1
competitive RT PCR donor CD34+ (7) 3.5 0.7 (p=0.21) 61
AML BM >90% blasts (9) 2.5
real time RT PCR donor CD34+ (1) 1.8x10-2 0.8-56 103
AML BM (9) 1.5x10-2-1.0
sequence specific RT
PCR
single cell cDNA library,
donor CD34+ (4)a
0.6b 1.5 63
single cell cDNA library,
K562 (4)
0.4b
real time RT PCR donor CD34+, rho dull (6) 0.19 2.0 (p=0.09) 62
MDS CD34+, rho dull
(13)
0.38
rho : rhodamine-123
a
 The frequency of WT1 positive cells within the CD34+ BM cells of 5 donors was estimated with single
cell RT-PCR and was 1.2%. b WT1/GAPDH
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Abstract
The pattern of X-chromosome inactivation (XCIP), or Lyonization can be used to distinguish
monoclonal from polyclonal cell populations in females. However, a skewed XCIP exists in
hematopoietic cells in approximately 40% of healthy elderly females, interfering with
interpretation of clonality assays. In hematopoiesis, an active stem cell pool is assumed to be
present within a larger population of inactive stem cells, with a continuous exchange of cells
between the two compartments. The assumption that the active stem cell pool size decreases
with age may explain the phenomenon of acquired skewing occurring by chance and predicts
the XCIP of this population to fluctuate. This fluctuation should be reflected in the XCIP of
peripheral granulocytes. We examined the XCIP for fluctuations in time in peripheral
granulocytes, monocytes and T cells of young, middle-aged and elderly healthy females. We
used an optimized HUMARA PCR assay that eliminates unbalanced DNA amplification. We
found no fluctuations in XCIP in any age group in up to 18 months follow-up. We conclude
that acquired skewing arises gradually in life without fluctuations in XCIP and that analysis at
multiple time points cannot distinguish monoclonal hematopoiesis from normal, skewed
hematopoiesis.
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Introduction
Lyonization has had the interest of oncologists since it was shown that it could be used to
assess the clonality of a population of (malignant) cells. The process of Lyonization, or X-
chromosome inactivation, takes place early in embryogenesis in all females.15 In every cell
one of the two X-chromosomes is inactivated, presumably to correct for the level of
expression of X-linked genes. Once one of the X-chromosomes has been inactivated
randomly, the progeny of that cell inherits the X-chromosome inactivation pattern (XCIP). As
a result most cell populations show a fifty-fifty distribution of inactivated paternal and
inactivated maternal alleles. Malignant cells are derived from a single cell and although
different subclones may develop, all malignant cells in a female patient will share the same
inactivated X-allele. This principle has been used to investigate tumors, both solid and
hematopoietic.104,105
The most frequently used clonality assay is based on a polymorphism in the Human Androgen
Receptor (HUMARA) gene. The polymorphism consists of a varying number of CAG repeats
(17-30) in the first exon of the gene. It has been shown that about 90% of the female
population is heterozygous at this locus.106 After PCR amplification of this locus, the two
alleles are present as two PCR products of different size. Discrimination between active and
inactive alleles can be made by digestion of the DNA with a methylation sensitive restriction
enzyme, such as HpaII, before PCR. Since the inactivated X-chromosome is heavily
methylated, it will not be digested, and only the inactivated allele will serve as a template for
the PCR.
In the last few years several technical difficulties have been described for this assay. It has
been shown that both saline contaminants and the number of cycles can influence the ratio of
PCR products.16,107 Both result in falsely skewed inactivation patterns. In this study we show
that the amplification of genomic DNA is also subject to preferential amplification with
respect to the methylation status of the DNA. We also show that digesting the DNA with a
restriction enzyme that is not sensitive to methylation can reverse this unequal amplification
of genomic DNA.
Another limitation for the use of XCIP for clonality assays is acquired skewing. Once a
population of cells has a certain distribution of alleles after Lyonization, this pattern has been
assumed not to change. However, several reports have shown an increase in the number of
females with a skewed XCIP in blood leukocytes with increasing age.26-29,35 The percentage
of females with a ratio of more than 75% of either allele in granulocytes may be as high as
40% after the age of 65. The skewing in T cells seems to lag behind, which may give rise to a
different XCIP for T cells and granulocytes. Precisely this pattern, skewed granulocytes with
non-skewed T cells, is thought to be indicative of malignant clonal myelopoiesis in patients
with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and
myeloproliferative syndromes (MPS).108-111
Studies in mice have shown that hematopoiesis is maintained by relatively few stem cells at
any given time point (~5% of all long-term self-renewing hematopoietic stem cells), while the
vast majority (~99%) of stem cells divides at least once during a longer period (57 days in
mice).112 This suggests a small percentage of active stem cells within the stem cell pool, and
that stem cells are switching between active and inactive status. If we assume that the size of
the active stem cell pool decreases with age, it is conceivable that fluctuations in the XCIP of
the active stem cells may occur. The frequency of these fluctuations would reflect the time
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that a stem cell contributes to hematopoiesis. This fluctuation should also be apparent in the
XCIP of peripheral granulocytes as these cells have a limited life span of several days.
Furthermore, this fluctuation should not be present in clonal, malignant hematopoiesis. To test
this hypothesis, we assessed the XCIP of granulocytes as well as T cells and monocytes of
young, middle-aged and elderly females over a prolonged observation period. We show that
no significant XCIP changes occur in any of the three age groups for a period as long as 18
months. We also show in elderly females an increase in the number of individuals with a
skewed XCIP as well as an increase in the degree of skewing. These results suggest that the
observed acquired skewing affects the whole of the stem cell population and that it develops
gradually during life. These results also implicate that analyses at multiple time points cannot
distinguish clonal hematopoiesis from polyclonal hematopoiesis with a skewed XCIP.
Materials and methods
Selection of granulocytes, monocytes and T cells from healthy donors
Peripheral blood samples were obtained from 35 healthy blood donors after written, informed
consent was obtained. All blood samples were separated in polymorphic nucleated cells
(PMNC) and mononuclear cells (MNC) using ficoll 1.077 density gradient centrifugation.
MNC were cryopreserved prior to cell sorting. PMNC were recovered from the pellet of the
gradient after erythrocyte lysis with ammonium chloride. PMNC were stored in 70% ethanol
at -20˚C or used directly for DNA isolation. Granulocytes (PMNC) appeared to be more than
95% pure by flowcytometric analysis based on light scattering properties. After thawing in the
presence of DNAseI, MNC were washed and stained with mouse monoclonal antibodies for
CD19 (PE conjugated) and CD3 (FITC conjugated) (Coulter Immunotech, Marseille, France).
Cells were sorted using a Coulter Epics Elite flowcytometer (Beckman Coulter, Fullerton,
CA, USA). T cells were defined as CD3 positive, CD19 negative. Monocytes were defined as
CD3 and CD19 negative, and having the appropriate scattering characteristics. After sorting,
the cells were prepared for DNA isolation.
DNA isolation, HpaII digestion and PCR
DNA from all cells was isolated with the Puregene DNA isolation kit (Gentra systems,
Minneapolis, MD, USA). DNA was diluted to 0.1 µg/µL. Digestion of 5 µL of a DNA sample
was performed overnight at 37˚C in a reaction mixture of 25 µL, containing 25 units of
concentrated HpaII (New England Biolabs, Hitchin, UK) with or without 5 units DdeI or 5
units RsaI (Life technologies, Gaithersburg, MD, USA) in 1x one-phor-all buffer PLUS
(Amersham Pharmacia, Uppsala, Sweden). After digestion, 5µL of this mixture was used for
PCR amplification of the HUMARA locus. The PCR mixture contained 300 nM forward
primer, 400 nM FITC-labeled reverse primer, 6% DMSO, 2.5 mM dNTP’s (Amersham
Pharmacia, Uppsala, Sweden), 1.5 mM MgCl2, 1x buffer II and 1.25 units AmpliTaq Gold
(Applied Biosystems, Foster City, CA, USA) in a total reaction mixture of 50 µL. Primer
sequences were: forward 5’-ccccaggcacccagaggc -3’, reverse 5’-gagaaccatcctcaccctgct -3’.
PCR was performed based on a protocol by Mutter et al.107: 7.5 minutes 95˚C, followed by
three rounds of 2.5 minutes 95˚C, 30 seconds 62˚C, 1 minute 71˚C, followed by 32 rounds of
45 seconds 95˚C, 30 seconds 62˚C, 1 minute 72˚C, followed by a single step of 10 minutes
72˚C.
Analysis of PCR products
PCR products were analyzed by electrophoresis on agarose or acrylamide gels, and the
relative abundance of the alleles was quantified. Analysis was performed on 4% agarose E-
gels (Invitrogen, Carlsbad, CA, USA). If the relative abundance of either allele was more than
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75%, or if the difference in size was less than 2 repeats (6 bp), analyses were repeated on
acrylamide gels. The relative abundance of alleles was quantified using a Gel Doc 1000 UV
detection system and Multi Analyst software (Biorad, Hercules, CA, USA) for agarose gels.
Acrylamide analysis was done using POP-4 acrylamide, genetic analyzer buffer and ‘310’
capillaries (Applied Biosystems, Foster City, CA, USA) in a P/ACE 5000 capillary
electrophoresis system equipped with a LIF detector and a argon laser at 488 nm (Beckman
Coulter, Fullerton, CA, USA) or in a ABI PRISM 310 genetic analyzer (Applied Biosystems,
Foster City, CA, USA). Reliability of quantification was tested by diluting two male DNA
samples into each other (with different sizes of alleles). Ratios between 20:80 and 80:20 gave
identical results for agarose and acrylamide analysis. More extreme ratios were quantified
more reliably with acrylamide electrophoresis; due to the higher background on agarose gels
low intensity bands are overestimated leading to inaccurate quantification of extreme ratios.
The presence of heteroduplexes on agarose gels did not influence the ratio of the correct
bands. The correlation for the dilution series on acrylamide was 0.9927 (R2). Duplicates were
always within 10% of each other. All samples were analyzed at least in duplicate. Several
samples were analyzed after independent HpaII digestion or independent cell sorting, and
these gave always results within 10% of previous experiments. The PCR ratio was calculated
by dividing the signal of the largest allele by the total signal of both alleles and multiplying
with 100%, unless otherwise indicated. Skewing was defined as a ratio more extreme than
75:25 or 25:75.
Results
Skewing in total genomic DNA and HpaII digested DNA
The ratio of paternal and maternal alleles of the X-chromosome in genomic DNA should
theoretically be 50:50 after amplification of the HUMARA locus (PCR ratio). In the initial
phase of the study we found an unequal amplification of alleles (more extreme than 60/40) in
the genomic DNA of peripheral granulocytes. This was observed in 8 out of 12 cases with a
skewed XCIP after HpaII digestion. The PCR ratio was in opposite directions before and after
HpaII digestion in all these cases (Table 1). This suggests a less efficient amplification of the
inactivated, methylated alleles. To improve the HUMARA PCR and to make the DNA more
accessible we digested the DNA of two donors (with equal, DN13, or unequal, DN11, PCR
ratios) with DdeI or RsaI and with or without HpaII prior to PCR (Figure 1). DdeI and RsaI
are methylation-insensitive enzymes that cut outside the HUMARA PCR target. The already
balanced PCR ratio of DN13 was not influenced by any treatment. In DN11, the PCR ratio of
undigested DNA (lane 1) was opposite to the PCR ratio found after HpaII digestion alone
(lane 4), as before. Digestion with DdeI resulted in an equal PCR ratio in the genomic DNA
(lane 2) while it did not influence the PCR ratio after HpaII digestion (lane 3). Digestion of
the DNA with RsaI resulted in very poor PCR signals (lanes 5, 6). The addition of DdeI
digestion in the HUMARA protocol reduced unbalanced amplification of genomic DNA to
less than 1% of cases (2 out of 263). Consequently we used the PCR ratio of the HpaII + DdeI
digested DNA as the most reliable value for XCIP. Cases were not evaluated in which the
PCR ratio after DdeI digestion alone was more than 60% or less than 40%.
Skewing in relation with age
Peripheral blood samples of 35 healthy blood donors were assessed for their XCIP. In Figure
2 we have plotted the XCIP value of the allele with the most intensity for each donor against
age. We found, as has been described before, that the prevalence of skewing of granulocytes
increases with age and that there is a trend towards a higher degree of skewing with
increasing age. In the youngest group of donors (age between 20 and 23), we found no cases
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Table 1: Opposite ratios of alleles after HUMARA PCR in genomic DNA and HpaII digested
DNA (inactive alleles).
donor nr. ratio upper/lower allele
genomic DNA HpaII digested DNA
11 72/28 27/73
2 94/6 36/64
6 37/63 62/38
25 38/62 73/27
17 31/69 67/33
47 30/70 74/26
9 79/21 40/60
12 82/18 30/70
Figure 1
DdeI digestion prevents unequal DNA amplification.
Shown are the HUMARA PCR results on agarose for two donors. DN 11 (upper panel) shows unequal
DNA amplification (1) and a skewed XCIP (4). DdeI digestion yields balanced DNA amplification (2)
and leaves the XCIP intact (3). Digestion with RsaI gives the same pattern but diminishes the PCR
signal (11, 12). The already equal DNA ratio of DN13 (lower panel) was not affected by any
treatment.
DN 13
allele B
allele A
allele A
allele B
1 2 3 4 5 6
DNA DdeI DdeI
HpaII HpaII
RsaI
72/24 52/48 28/72 27/73 50/50 23/77
55/45 47/53 50/50 45/55 54/46
DN 11
RsaI
HpaII
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Figure 2
Skewing increases with age.
Plotted are the HUMARA PCR ratios after HpaII and DdeI digestion against the age of each donor.
The PCR ratio is given as the percentage of the most abundant allele. All points are the means of at
least duplicates.
of skewing (ratio more extreme than 75:25). The average PCR ratio in this group was 64%
(54-74%). In the age group between 43 and 55, 4 out of 12 donors (25%) had a skewed XCIP
of more than 75%. The average PCR ratio in this group was 70% (52-88%). In the eldest
group (age between 61 and 67) 6 out of 15 (40%) donors had a skewed XCIP of more than
75%. The average PCR ratio in this group was 73% (50-97%). The average PCR ratio was
only statistically different between the young and the old group (p=0.04).
X-chromosome inactivation patterns over time in granulocytes
Twenty-six of the 35 healthy donors, in three different age groups, were evaluated at multiple
time points for fluctuations in their XCIP. Changes in the XCIP of granulocytes of more than
20% have not been observed in any of the donors. In the young age group six out of eight
individuals were evaluated for their XCIP in granulocytes at multiple time points. The median
follow-up time in this group was 7 months, ranging from 4 to 13 months. The mean variation
between samples was 3%, ranging from 1 to 7%. In the middle-aged group eight out of 12
individuals were evaluated at multiple time points with a mean follow-up time of 12 months
(4.5-18). The mean variation in this group was 3% (0-7%). In the elderly donor group 12 out
of 15 donors were evaluated at multiple time points. The mean fluctuation in XCIP in this
group was 7% (0-18%), the mean follow-up time was 13 months (4.5-18). The age, follow-up
time and the variation between samples are given for each donor in Figure 3. The median time
between samples was 4.8 months for the whole group (2 weeks-18 months).
Granulocytes compared to monocytes and T cells
The XCIP in the monocytes, T cells and granulocytes was compared in 25 of the 35 donors.
We tested 14 of the 15 elderly, nine of the 12 middle-aged and two of the eight young donors,
in view of the more prevalent skewing in granulocytes of the older donors. The average XCIP
value for all three cell types are plotted in Figure 4 for all 25 donors. Also in these cell
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Figure 3
The XCIP in granulocytes remains stable over time in all age groups.
Plotted are the XCIPs against time of peripheral granulocytes for all 26 donors of whom follow-up
samples were evaluated. The XCIP is represented by the PCR ratio after HpaII and DdeI digestion.
(a) All donors between 61 and 67 years of age (). (b) All donors between 43 and 55 years of age
() and between 20 and 23 years of age (∆). All points are the means of at least duplicates.
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fractions no fluctuations of more than 20% in XCIPs were found with one exception. In donor
9 a single time point showed a significant difference in XCIP in the T cells as compared to
samples of other time points, after multiple analyses (Figure 5a) The granulocytes of the same
sample did not show this fluctuation.
The mean difference between monocytes and granulocytes of the same donor was 2% and the
difference was always less than 20%. In general T cells had less extreme XCIPs than
granulocytes. Eighteen out of 25 cases showed less extreme skewing of XCIP in the T cells
than in the granulocytes, with an average difference of 14% (1-45%). In 7 cases the T cells
showed more extreme skewing than the granulocytes, with an average difference of 6% (1-
12%). In 6 cases the granulocytes had an XCIP value of more than 75% while the T cells had
an XCIP value of less than 75%. Of these, a difference of more than 20% in XCIP between T
cells and non-T cells was observed in only 3 cases (Figure 5c). Interestingly, in 6 donors a
difference was seen between T cells and non-T cells that was less than 20%, but remained
stable for up to 17 months with analyses at four different time points (Figure 5d).
Discussion
Acquired skewing of XCIP in hematopoietic cells cannot be distinguished from malignant,
clonal hematopoiesis in elderly females with the tests that are available today. We
investigated if the skewed XCIP in elderly females is prone to fluctuations, in order to
distinguish normal, skewed hematopoiesis from monoclonal, malignant hematopoiesis.
Fluctuations in XCIP are conceivable if we assume the size of the active stem cell pool to
decrease with age. Skewed hematopoiesis may occur by chance if the pool of active stem cells
is sufficiently small. Fluctuations in XCIP in such a small stem cell pool are likely to occur if
we assume this pool to be part of a larger, non-skewed, resting stem cell pool, with cells
switching between active or resting status. In mice, a study by Cheshier et al. estimates the
switching of stem cells between active and inactive status to be 8% per day.112 The authors
also show that 99% of stem cells enter cell cycle at least once in 57 days, implying that
fluctuations, if they occur, should be evident within a few months. However, a study by
Abkowitz et al. shows a difference between hematopoietic stem cells (HSC) from murine and
feline origin.113 A difference was observed in number of HSC (8 HSC per 105 nucleated bone
marrow cells (NBMC) and 6 HSC per 107 NBMC respectively) and in HSC replication (1
replication per 2.5 weeks and 1 replication per 8.3 to 10 weeks respectively). Wang et al.
estimated the number of HSC in humans to be even less frequent (1 HSC per 107 NBMC)114
If fluctuations do occur in the XCIP of the active stem cell pool, these fluctuations should be
reflected in the XCIP of peripheral granulocytes. However, we did not observe fluctuations in
the XCIP of leukocytes of any donor during a follow-up of up to 18 months. The only
exception was DN 9, whose T cells showed a fluctuation in XCIP. This does not reflect a
fluctuation of the XCIP of the active stem cells at that moment, as the granulocytes at that
time point did not show this fluctuation. More likely is the explanation that this sudden
skewing in the T cells was the result of an expansion of one particular T cell clone due to an
infection. Abkowitz et al. showed that in cats skewing of XCIP of hematopoietic cells arises
gradually during life without the occurrence of fluctuations from one allele to the other.36
Furthermore, Tonon et al. observed that the XCIP of hematopoietic cells remain stable for a
period of 12 to 24 months in healthy human donors.29 However, the authors did not present
data on the number or the age of individuals, nor on the number of samples that were tested. If
fluctuations do occur after all, they occur with such a low frequency that they are not of
practical use. The lack of fluctuations could imply that the active stem cell population does
not decrease sufficiently for fluctuations to become apparent or that fluctuations occur much
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Figure 4
Average XCIP of granulocytes, monocytes and T cells.
The XCIP, represented by the PCR ratio after HpaII and DdeI digestion, is plotted for the
granulocytes, monocytes and T cells of 25 donors. The values for the different cell types of the same
donor are connected. All points are the means of at least duplicates.
slower. Another explanation for the lack of fluctuations in our study is acquired skewing
affecting the whole of the stem cell compartment. This could be caused by clonal drift due to
a stochastic process.28 Other explanations are based on genetic differences. A somatic
mutation may lead to clonal domination of a single cell, as is the case in malignant
hematopoiesis. Alternatively, polymorphisms in genes located on the X-chromosome may
lead to selection of cells with one particular active X-chromosome and to a skewed XCIP.26,27
Such polymorphisms should be present in genes regulating the decision of self-renewal or
differentiation after stem cell division, or in genes affecting growth rate or survival of cells.
Abkowitz et al. have shown in cats that acquired skewing of XCIP is likely to be caused by a
polymorphic gene on the X-chromosome.36 Recently Christensen et al. showed that this is
also the case in humans through a study of XCIPs in elderly, monozygotic twins.37 The
authors showed that the XCIP of the majority of co-twins was skewed in the direction of the
same allele. In addition, the degree of skewing between co-twins was strongly correlated.
Also Vickers et al. showed a genetic influence on the development of acquired skewing in
human peripheral blood granulocytes.34 These findings correlate well with the lack of
fluctuations in XCIP in time. It also makes it less likely that very slow fluctuations occur that
we would have missed in our study.
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Figure 5
XCIP of granulocytes, monocytes and T cells over time.
The percentage of the largest allele after HUMARA PCR (after HpaII and DdeI digestion) is plotted
against the follow-up time for four donors. (a) DN9: The T cells show a fluctuation in XCIP while
granulocytes are stable. (b) DN18: No fluctuation in XCIP for all cell types and no difference between
cell types. (c) DN16: XCIP in T cells is consistently much less skewed than those of granulocytes and
monocytes. (d) DN12: A small but consistent difference in XCIP between T cells on the one hand and
granulocytes and monocytes on the other. All points are the means of at least duplicates.
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One of the reported problems with the HUMARA assay for the assessment XCIP is unequal
amplification of alleles.16,107 As the HUMARA alleles differ in the number of CAG repeats in
exon 1, the shortest allele may be preferentially amplified during PCR. For this reason,
genomic DNA is generally amplified along with the HpaII digested DNA, as the unequal
amplification might be similar in both samples. However, in the initial phase of our study we
only observed skewed PCR ratios in genomic DNA when there was also skewing in the HpaII
digested DNA. Furthermore, this skewing was always in the opposite direction compared to
the skewing in the HpaII digested DNA. This implied that there is a difference in
amplification efficiency between the DNA of the methylated X-chromosome and other DNA.
Such a phenomenon is only apparent in skewed samples, where the ratio of maternal and
paternal alleles in the inactivated X-chromosomes is exactly opposite to the ratio in the active
X-chromosomes. Digesting the DNA with DdeI results in excision of a 523 bp fragment from
the X-chromosome that contains the HUMARA PCR locus. This digestion fully prevented the
unequal amplification. When the genomic DNA was digested with DdeI, the PCR ratio was
almost always 50% (with an error margin of 10%), even when the XCIP was extremely
skewed. In rare cases (2 out of 263) we still observed an unbalanced amplification in the
genomic DNA of more than 60% of either allele. In these cases contaminating salts could
influence the amplification of alleles.107 Alternatively, the difference in length of alleles could
indeed lead to a different amplification efficiency in these cases.16 We decided to exclude
these samples from our analysis.
We conclude that the XCIPs of leukocytes of elderly healthy females do not fluctuate in time,
and that the development of a skewed XCIP is a slow, gradual process. This means that no
distinction can be made between normal skewed hematopoiesis and clonal, malignant
hematopoiesis in elderly females based on fluctuations in the XCIP. However, the HUMARA
PCR can still be useful for XCIP studies in younger females and in the investigation of solid
tumors. Secondly, we conclude that our improved HUMARA PCR leads to a more reliable
determination of XCIPs.
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Abstract
The most widely used technique for determining clonality based on X-chromosome
inactivation is the human androgen receptor gene polymerase chain reaction (PCR). The
reliability of this assay depends critically on the digestion of DNA before PCR with the
methylation sensitive restriction enzyme HpaII. We have developed a novel method for
quantitatively monitoring the HpaII digestion in individual samples. Using real time
quantitative PCR we measured the efficiency of HpaII digestion by measuring the
amplification of a gene that escapes X-chromosome inactivation (XE169) before and after
digestion. This method was tested in blood samples from 30 individuals: two healthy donors
and 28 patients with myelodysplastic syndrome. We found a lack of XE169 DNA reduction
after digestion in the granulocytes of two MDS patients leading to a false polyclonal X-
chromosome inactivation pattern (XCIP). In all other samples a significant reduction of
XE169 DNA was observed after HpaII digestion. The median reduction was 220-fold,
ranging from a ninefold to a 57000-fold reduction. Also paraffin-embedded malignant tissue
was investigated from two samples of patients with mantle cell lymphoma and two samples of
patients with colon carcinoma. In three of these cases inefficient HpaII digestion led to
inacurate XCIP ratios. We conclude that monitoring the efficiency of the HpaII digestion in a
human androgen receptor gene PCR setting is both necessary and feasible.
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Introduction
X-chromosome inactivation has been widely used to establish the clonal nature of
malignancies. X-chromosome inactivation, also known as Lyonization, occurs early in
embryogenesis and involves the random inactivation and methylation of either of the two X-
chromosomes in all female cells.15 Once established, the X-chromosome inactivation pattern
(XCIP) of a particular cell will be transferred to all the progeny of that cell. As a result a
normal cell population of a healthy female usually shows a 50:50 ratio of inactivated paternal
and inactivated maternal alleles. Since malignant cells are derived from a single precursor cell
all tumor cells contain the same inactivated X-chromosome, resulting in a monoclonal XCIP.
One of the most important assets of clonality analysis is that monoclonality is always related
to the first transforming mutation in the multistep pathogenesis of a tumor. This has been of
particular importance in the investigation of pre-malignant lesions. For instance, clonality of
suspected pre-malignant lesions has been confirmed in ovarian endometrial cysts,115
Langerhans’ cell histiocytosis116 and atypical adenomous hyperplasia of the lung.117 Clonality
studies have also been used for the investigation of a common neoplastic origin of different
cell types within a tumor118-120 or multiple tumor loci in the same patient.121 Analysis of
clonality is of practical use when neoplastic and reactive conditions present with similar
clinical symptoms, as in the vascular lesions of primary (clonal) and secondary (polyclonal)
pulmonary hypertension122 and in idiopathic hypereosinophylic syndrome (clonal) and
reactive eosinophilia (polyclonal).123 Also, clonal hematopoiesis has been shown to be
predictive for the development of therapy related myelodysplastic syndrome (MDS) or acute
myeloid leukemia (AML) in non-Hodgkin’s lymphoma patients after autologous bone
marrow transplantation.124
The most widely used method used most for XCIP determination utilizes a highly
polymorphic trinucleotide repeat in the Human Androgen Receptor gene (HUMARA).
Approximately 90% of the female population is heterozygous for this polymorphism.106 The
combination of laser microdissection and the HUMARA polymerase chain reaction assay
(PCR)125 allows clonality analysis in virtually all tissue samples of females. After PCR
amplification of the HUMARA locus, the two alleles are present as two PCR products of
different size. Discrimination between active and inactive alleles can be made by digestion of
the DNA with a methylation sensitive restriction enzyme, such as HpaII, before PCR. Since
the inactivated X-chromosome is heavily methylated, it will not be digested, and only the
inactivated allele will serve as a template for the PCR. Essential for this method is the
digestion with HpaII, with incomplete digestion resulting in false polyclonality. Until now
digestion of male DNA has been used for monitoring the efficiency of the HpaII digestion.
However, in this way no information is obtained about the efficiency of digestion in
individual samples.
We have developed a method that allows monitoring of HpaII digestion efficiency in
individual samples. Several genes that escape X-inactivation have been identified on the X-
chromosome. XE169 is one of the genes that escape X-inactivation126,127 and is located
between Xp11.21 and Xp11.22 within a domain containing at least 5 other genes, all escaping
X-inactivation.128 Digestion of HpaII sites in the XE169 gene is therefore not hindered by
methylation and should result in the digestion of both alleles. We designed a real time
quantitative PCR spanning an HpaII site in the XE169 gene. We expressed the efficiency of
HpaII digestion as the relative reduction of target DNA by comparing the amount of XE169
DNA before and after digestion. We investigated peripheral blood (PB) and bone marrow
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(BM) samples from MDS patients. MDS is a malignant bone marrow disease with frequent
progression to AML. In MDS myeloid cells in the PB and BM generally clonal,39,40 but
polyclonal myeloid cells are seen in a number of cases.39-41 We investigated the efficiency of
HpaII digestion in MDS patient samples with either a clonal or a polyclonal XCIP at
diagnosis. Additionally, four paraffin-embedded tissue sample were investigated.
Materials and methods
Sampling
PB or BM samples were obtained from two healthy blood donors (one male, one female) and
28 female MDS patients after obtaining informed consent. MDS patients participated in the
Clonal Remission after Intensive Antileukemic Treatment (CRIANT) study (study nr. 06961)
of the European Organization for Research and Treatment of Cancer (EORTC) in framework
of the Biomed-2 program BMH4-96-0357. Of six patients both bone marrow and blood cells
were investigated. Of 21 patients also monocytes or T cells or both were investigated. Of
three patients one or more follow-up samples were investigated. The DNA of seven patients
and one male healthy donor was digested twice with HpaII on two different occasions. The
DNA of the healthy female donor was used in five different digestions. In total, 77 different
samples were used for HpaII digestion. In addition, four archival paraffin-embedded tissue
samples were investigated; two samples from the lymph nodes of two patients with mantle
cell lymphoma and two samples from colon carcinoma lesions of two different patients.
Selection of granulocytes, monocytes and T cells from PB and BM
Preparation of cells was performed as described earlier.33 All samples were separated in
polymorphic nucleated cells (PMNC, granulocytes) and mononuclear cells (MNC) using
ficoll 1.077 density gradient centrifugation. Granulocytes (PMNC) appeared to be more than
95% pure by flowcytometric analysis based on light scattering properties. MNC were washed
and stained with mouse monoclonal antibodies for CD19 (PE conjugated) and CD3 (FITC
conjugated) (Coulter Immunotech, Marseille, France). Cells were sorted using a Coulter Epics
Elite flow cytometer (Beckman Coulter, Fullerton, CA, USA). T cells were defined as CD3
positive, CD19 negative. Monocytes were defined as CD3 and CD19 negative, and having the
appropriate scattering characteristics. After sorting, the cells were prepared for DNA
isolation.
DNA isolation, HpaII digestion and HUMARA PCR
DNA was isolated with the Puregene DNA isolation kit (Gentra systems, Minneapolis, MN,
USA), both for the hematopoietic samples and the paraffin-embedded samples according to
the protocols of the manufacturer. Subsequent HUMARA analysis was performed as
described earlier.33 Digestion of 0.5 µg of DNA was performed for at least 16 hours at 37˚C
in a reaction mixture of 25 µL, containing 5 units DdeI (Life technologies, Gaithersburg, MD,
USA) and with or without 25 units of concentrated HpaII (New England Biolabs, Hitchin,
UK) in 1 x one-phor-all buffer PLUS (Amersham Pharmacia, Uppsala, Sweden). After
digestion, 5µL of this mixture was used for PCR amplification of the HUMARA locus. The
PCR mixture contained 300 nM forward primer, 400 nM FITC-labeled reverse primer, 6%
DMSO, 2.5 mM dNTP’s (Amersham Pharmacia, Uppsala, Sweden), 1.5 mM MgCl2, 1x
buffer II and 1.25 units AmpliTaq Gold (Applied Biosystems, Foster City, CA, USA) in a
total reaction mixture of 50 µL. Primer sequences were: forward 5’-ccccaggcacccagaggc -3’,
reverse 5’-gagaaccatcctcaccctgct -3’. PCR conditions were: 7.5 minutes 95˚C, followed by
three rounds of 2.5 minutes 95˚C, 30 seconds 62˚C, 1 minute 71˚C, followed by 32 rounds of
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45 seconds 95˚C, 30 seconds 62˚C, 1 minute 72˚C, followed by a single step of 10 minutes
72˚C.
Analysis of PCR products
PCR products were analyzed as described before by electrophoresis on agarose or acrylamide
gels, and the relative abundance of the alleles was quantified.33 Analysis was performed on
4% agarose E-gels (Invitrogen, Carlsbad, CA, USA). If the relative abundance of either allele
was more than 75% or if the difference in size was less than 2 repeats (6 bp), analyses were
repeated on acrylamide gels. The relative abundance of alleles was quantified using a Gel Doc
1000 UV detection system and Multi Analyst software (Biorad, Hercules, CA, USA) for
agarose gels. Acrylamide analysis was done using POP-4 acrylamide, genetic analyzer buffer
and ‘310’ capillaries (Applied Biosystems, Foster City, CA, USA) in a P/ACE 5000 capillary
electrophoresis system equipped with a LIF detector and a argon laser at 488 nm (Beckman
Coulter, Fullerton, CA, USA) or in a ABI PRISM 310 genetic analyzer (Applied Biosystems,
Foster City, CA, USA). All samples were analyzed at least in duplicate. The XCIP ratio was
calculated by dividing the signal of the largest allele by the total signal of both alleles and
multiplying with 100%. Samples were considered polyclonal if the XCIP ratio was between
75:25 and 25:75. More extreme XCIP ratios were considered to be clonal.
real time XE169 PCR
Quantitative real time PCR was performed with the ABI/PRISM 7700 Sequence Detection
System for quantification with a fluorescent probe and the 5700 Sequence Detection System
for quantification with Sybr Green and melting curve analysis (Applied Biosystems, Foster
City, Ca, USA). Primer sequences were: forward: 5’-gcttggtgtgacgcaacgta-3’, reverse: 5’-
gccttcgccaccacagttca-3’. The sequence of the TET-labelled probe was: 5’-
aggacaccccgcggaaggatcc-3’. PCR conditions were as follows: 10 min. 95°C followed by 45
cycles of 15 sec 95°C and 1 min. 57°C, with data collection in the last 30 seconds. For all
PCRs 1.25 U AmpliTaq Gold, 5µL 10xbuffer A or 5 µL 10xsybr green buffer, 5 mM MgCl2
(all Applied Biosystems, Foster City, Ca, USA) and 250 mM dNTPs (Pharmacia, Uppsala,
Sweden) were used in the reaction mixture. Primer concentrations were 900 nM and the probe
concentration was 200 nM. All PCRs were performed in a total volume of 50 µL.
The reduction of XE169 copies was calculated by comparing the cycle threshold (Ct) value of
two aliquots of the same sample; both were treated identical with the exception of the
presence or absence of HpaII in the digestion mixture. This fold reduction was calculated by
the formula: fold reduction = 2((Ct with HpaII)-(Ct without HpaII)). The efficiency of the PCR was
determined from a serial dilution series of a digestion mixture of a DNA sample without
HpaII in digestion mixture and was 1.93, expressed as the fold increase in fluorescence per
PCR cycle, showing the validity of the method used for quantification. The correlation
coefficient (R2) for this dilution series was 0.996. PCRs for each sample were performed in
duplicate.
Results
The HpaII digestion of the DNA from mononuclear cells of the peripheral blood of a healthy
female donor was followed in time to monitor the efficiency of digestion. The amount of
XE169 DNA was measured before and after one, two, three, four or 24 hours of HpaII
digestion (Figure 1). After four hours the digestion reached a plateau phase with an almost
500-fold reduction of XE169 DNA. All further samples were digested for at least 16 hours to
ensure maximal digestion.
38 J.P.van Dijk
Figure 1
HpaII digestion time course of DNA of a healthy female donor.
The digestion time in hours is plotted against the fold reduction of XE169 DNA after HpaII digestion.
For each time point the amount of XE169 DNA was compared with real-time quantitative PCR
between a reaction mixture with or without HpaII enzyme. The fold reduction after digestion reached
a plateau between 4 and 24 hours. The DNA was isolated from the mononuclear cells of the peripheral
blood.
To test the HpaII digestion in individual DNA samples, 70 HpaII digestions were analyzed
from 28 different female MDS samples and one healthy male donor sample. The importance
of measuring HpaII performance in individual samples was shown in DNA samples from
granulocytes of two patients. The reduction after HpaII digestion measured with the XE169
PCR was respectively 1.1- and 0.7-fold with sybr green detection and 1.9-fold for both
samples with a fluorescent probe. These numbers were within the error margin of quantitative
PCR, which cannot reliably detect differences less than 2-fold. This implied that the HpaII
digestion did not function in these samples. Using the HUMARA PCR, the same DNA
samples showed a polyclonal XCIP ratio of 43:57 and 47:53 respectively. DNA from
monocytes was also available of these patients. Analysis of HpaII digestion of this material
yielded reductions of, respectively, 1400- and 39-fold using the XE-169 control assay and
clonal XCIP ratios of 2:98 and 81:19 using the HUMARA PCR assay (Figure 2). Also the
other 64 digestions of the DNA of 26 patients and the male donor showed a significant
reduction of XE169 DNA (more than fivefold) after HpaII digestion, ranging from a ninefold
to a 57000-fold reduction (median, 220-fold) (Figure 3).
Reproducibility of digestion and analysis was evaluated in eight samples that were digested in
two independent experiments, with Sybr Green analysis in one and fluorescent probe analysis
in the other experiment. The mean difference between two digestions was 2.3-fold, ranging
from 1.2- to 3.7-fold indicating that the HpaII digestion is a reproducible process and that the
Sybr Green and fluorescent probe analyses are comparable. The variation in the duplicate
digestions was smaller than the variation in individual samples (p<0.0001) indicating that the
digestibility of a sample is more dependent on the quality of the sample than on the
performance of the HpaII enzyme. DNA from archival, paraffin-embedded tissue was also
tested for digestibility to check the feasibility of the described method for this kind of
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Figure 2
False polyclonality in the granulocytes of two MDS patients.
The X-chromosome inactivation pattern (XCIP) for four DNA samples of two MDS patients is
represented by the relative intensity of the two alleles after HUMARA PCR. The two alleles were
visible as peaks in the electropherogram of the PCR products, and are indicated with A and B. The
relative intensities of the peaks are given as percentages. In both patients a polyclonal XCIP in the
granulocytes coincided with a failure of HpaII digestion, whereas a clonal XCIP in the monocytes
coincided with successful HpaII digestion. The success of HpaII digestion is expressed as the fold
reduction of XE169 DNA measured with real-time quantitative PCR after digestion.
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material. Four samples were tested from malignant tissue with different amounts of malignant
cells. Two samples were biopsies taken from lymph nodes of two patients with mantle cell
lymphoma. These samples contained more than 95% of malignant cells. Two other samples
were obtained from patients with colon carcinoma. In both samples the amount of malignant
cells was 60%. Although the amount of DNA extracted from these samples was less than the
amount typically obtained from blood samples, both the XE169 and HUMARA PCRs were
successful before and after HpaII digestion. In both colon carcinoma samples the reduction of
XE169 DNA after HpaII digestion was less than 10-fold. This led, in combination with the
low percentage of tumor cells in these samples, to a polyclonal XCIP ratio instead of the
expected skewed XCIP ratio. For one of the lymphoma samples the reduction of XE169 DNA
was 49-fold after HpaII digestion, corresponding with a monoclonal XCIP pattern after
HUMARA PCR. The other lymphoma sample showed a 4.4-fold reduction of XE169 DNA
after HpaII digestion. In this case the XCIP ratio after HUMARA PCR was skewed, but not
fully monoclonal (Table 1). These results show the necessity of HpaII digestion monitoring,
especially in paraffin-embedded tissue.
Discussion
We have developed a new, quantitative way to monitor the efficiency of digestion of DNA
with the HpaII restriction enzyme in the context of clonality analysis with the HUMARA
PCR. This method is based on measuring the reduction after digestion of a gene that escapes
X-inactivation (XE169). We found a differential reduction in the amount of XE169 copies in
granulocytes and monocytes in two patients after HpaII digestion. In both patients the lack of
XE 169 reduction in granulocytes correlated with a polyclonal XCIP measured with
HUMARA PCR. In contrast, the monocytes, originating from the same myeloid precursor
cells as granulocytes, showed a clonal XCIP and HpaII digestibility in both patients. This
indicated that the lack of HpaII digestion in the DNA from the granulocytes was probably due
to poor DNA quality and that the XCIP was falsely polyclonal in these cells.
In the blood samples of all 30 individuals tested, the monitoring of HpaII digestion efficiency
was feasible by comparing the amount of XE169 DNA before and after digestion. A
significant reduction in XE169 DNA was observed in 66 HpaII digestions of DNA from 28
different female MDS samples and two healthy donors. We found a large variation in the
reduction of XE169 copies after HpaII digestion in individual samples. This was not
dependent on the performance of the HpaII digestion, as independent digestions of the same
sample showed much less variation. The large variation in individual samples may be caused
by a difference of DNA quality between samples.
The HpaII digestion efficiency was also monitored for DNA from four archival, paraffin-
embedded tissue samples. In one of two lymphoma samples adequate HpaII digestion
monitored by XE169 DNA reduction corresponded with the expected monoclonal XCIP ratio.
The other three samples showed a XE169 DNA reduction of less then 10-fold after HpaII
digestion, indicating an inefficient reaction. In the other lymphoma sample, the corresponding
HUMARA PCR showed a skewed XCIP ratio instead of the monoclonal pattern expected
from the more than 95% of tumor cells in this sample. In the two colon carcinoma samples the
inefficient HpaII digestion combined with the low tumor cell percentage (60%) led to
polyclonal XCIP ratios after HUMARA PCR. These results imply that DNA from paraffin-
embedded tissues may be of poorer quality than DNA from blood samples and stress the
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Figure 3
HpaII digestion is successful in the majority of samples.
The quantity of XE169 in a reaction mixture without HpaII (in arbitrary units) is plotted against the
fold reduction after HpaII digestion for 70 different digestions of the DNA of 28 female MDS patients
and one male healthy donor. The difference before and after digestion was not significant in four
digestions of the DNA of granulocytes of two patients. In the other 66 cases a significant reduction
(more than fivefold) of XE169 DNA was observed after HpaII digestion.
importance of monitoring of HpaII digestion efficiency, especially in paraffin-embedded
material.
Incomplete HpaII digestion leads to a false polyclonal background signal in the XCIP
determined by HUMARA PCR. The magnitude of the resulting error is dependent on the
actual XCIP. If the reduction in DNA is 10-fold then an XCIP ratio of 100:0 would become
91:9, a ratio of 75:25 would become 70:30 and a ratio of 50:50 would remain the same. As the
margin of error for the XCIP determined by HUMARA PCR is approximately 10%16, a 10-
fold reduction of DNA after HpaII digestion would suffice in this setting. Reductions of less
than 10-fold diminish the accuracy of the XCIP determination as has been shown in two
blood and three paraffin-embedded tissue samples.
Clonality analysis based on XCIPs is generally a reliable technique. For most tissues in the
human body non-random, or skewed XCIPs that are not related to clonality are found in only
a minority of individuals. This can be identified quite easily by analysis of normal cells
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Table 1 Reduction of XE169 DNA and XCIP ratios after HpaII digestion in DNA from
paraffin-embedded tissue.
tissue % tumor cells XE169 reduction XCIP ratio
non-Hodgkin’s lymphoma #1 >95 49-fold 9:91
non-Hodgkin’s lymphoma #2 >95 4.4-fold 76:24
colon carcinoma #1 60 4.0-fold 56:44
colon carcinoma #2 60 7.1-fold 59:41
adjacent to the suspected sample.115,122,129-132 An exception is the mammary gland, which is
composed of monoclonal patches in healthy donors forestalling the distinction between
hyperplastic and neoplastic lesions based on clonality.133 Excessively skewed XCIPs are also
found in hematopoietic cells of healthy elderly females (~40% of individuals over 60 years of
age).26-28 This acquired skewing is mainly because of selective pressure for one or more
genetic differences between the two X-chromosomes.34,36,37
Apart from false clonality, false polyclonality may be observed. This can be due to the
presence of contaminating normal cells such as infiltrating inflammatory cells. Recently it has
been shown that unstable methylation may also cause false polyclonality in aberrant crypt foci
of the human colon.134 A third, technical reason for false polyclonality is incomplete HpaII
digestion of the active, unmethylated X-chromosomes. We have shown that this can be
identified by measuring the reduction after digestion of a gene that escapes X-chromosome
inactivation.
We conclude that monitoring the efficiency of the HpaII digestion in a HUMARA PCR
setting is both necessary and feasible. With quantitative real-time PCR on the XE169 gene
false polyclonality due to ineffective HpaII digestion can be eliminated.
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Abstract
In the present study we analyzed the cytogenetic and clonal status of patients with high risk
myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) after MDS, before and
after intensive antileukemic treatment. Cytogenetic analysis was performed using standard
banding techniques and Fluorescent In Situ Hybridization (FISH). Clonality was evaluated by
analysis of the X-chromosome inactivation pattern (XCIP) using the human androgen
receptor gene (HUMARA) polymerase chain reaction (PCR) assay in female patients. Patient
samples were analyzed at diagnosis and in morphological complete remission (CR). All
patients received high-dose chemotherapy for remission induction and consolidation therapy.
Of 312 evaluable patients, 173 reached CR after one or two remission induction courses
(55.4%). The actuarial survival rate at 3 years was 31.7%. A cytogenetic aberration was
present in 58% of patients at diagnosis. A cytogenetic complete remission was observed in 32
out of 46 patients with a cytogenetic aberration at diagnosis (69.6%). Patients with a
cytogenetic remission tended to have a better disease free survival than patients with
persisting abnormalities (p = 0.087). The most important difference between the two groups
was the higher relapse rate in the non-responders (93 vs 57%, p = 0.015). This indicates the
importance of cytogenetic analysis in CR. At diagnosis a clonal XCIP was observed in the
myeloid cells of 62 of 69 patients (90%) and in the T cells of 19 of 61 patients (31%). A
response of the XCIP was observed in myeloid cells in 12 out of 22 patients in CR (55%) but
not in the T cells of any of 16 investigated patients. Of the patients with clonal myeloid cells
in CR, a clonal XCIP was observed in the T cells both at diagnosis and in CR in 6 of 7
patients (86%), indicating that a biological skewing of XCIP may mask a clonal response to
treatment in a substantial portion of patients. Clonality of myeloid cells did not significantly
influence the survival of patients at diagnosis or in CR. We conclude that intensive
antileukemic treatment of high-risk MDS patients leads to a molecular response in the
majority of patients. Cytogenetic analysis in CR is important for the prediction of disease free
survival and the incidence of relapse. Biological skewing of Lyonization interferes with the
interpretation of XCIP in remission.
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Introduction
The disease course of myelodysplastic syndromes (MDS) ranges from a chronic course that may
span years to a rapid progression to acute myeloid leukemia (AML). Refractory anemia (RA) and
RA with ring sideroblasts (RARS) are characterized by a low risk of transformation to AML and a
median survival usually in excess of 30 months.135 In contrast, the median survival of patients with
refractory anemia with excess of blasts (RAEB) or RAEB in transformation (RAEBt) is less than 12
months.2,136 The karyotype is an additional prognostic factor for survival in MDS.137,138 The
international prognostic scoring system (IPSS), based on cytogenetic abnormalities, marrow blasts,
and peripheral blood cytopenias, identifies patients in whom the median survival is less than one
year.3 In these high-risk patients, intensive chemotherapy followed by allogeneic or autologous stem
cell transplantation (SCT) leads to a substantially better survival.139 No prospective randomized
studies have compared allogeneic and autologous SCT, for ethical reasons. However, an analysis
comparing patients with or without a donor, mimicking such a randomized study, showed a similar
outcome for the two regimens based on intention-to-treat.140 Although intensive chemotherapy leads
to complete remission (CR) rates of 50% to 64% of the patients,11,139,141-143 the relapse rate in
patients achieving CR is still high, leading to a four-year survival of only 26%.139 Clearly, a reliable
parameter is needed to predict outcome of treatment in patients who have reached CR.
We analyzed the molecular status of high-risk MDS patients and patients with AML supervening
after MDS both at diagnosis and at CR after antileukemic treatment. Objectives were to estimate the
success rate of treatment at a cytogenetic or clonal level in CR and to assess the impact of a
molecular response for the disease free survival (DFS). All patients were treated in a large European
multi-center study. After a common remission induction and consolidation course, patients with a
donor were scheduled for allogeneic SCT and patients without a donor were randomized between
autologous SCT and a second consolidation course. Cytogenetic analysis was performed with
standard banding techniques and FISH (fluorescent in situ hybridization). The clonality analysis
consisted of the determination of the X-chromosome inactivation patterns (XCIP) of female patients.
A random XCIP represents a polyclonal population of cells while a non-random pattern is indicative
of a clonal cell population. Both analyses were assessed for their predictive value at diagnosis and in
CR after consolidation, regardless of the administered post-consolidation therapy.
Methods
Patient selection criteria
Patients were eligible for the study if they had: (1) RA, RARS or RAEB with <10 percent blasts in
the marrow and multiple chromosomal abnormalities, (2) RAEB with >10 percent blasts in the bone
marrow, (3) RAEB in transformation (RAEBt), (4) chronic myelomonocytic leukemia (CMML)
with a neutrophil count of >16 x 109/L or a monocyte count of >2.6 x 109/L in the blood or >5 %
blasts in the bone marrow, or (5) secondary AML supervening proven MDS of more than 6 months
duration (AML-MDS).
Exclusion criteria were as follows: (1) age less than 16 years or more than 60 years, (2) previous
intensive chemotherapy, and/or radiotherapy for MDS or AML, (3) treatment with biological
response modifiers and/or low dose cytarabine within two months prior to entry; (4) no informed
consent, (5) performance status WHO-scale 3 or 4, (6) life expectancy of < three months, (7)
creatinin and/or bilirubin >1.5 times the upper normal limit. Informed consent of each patient was
obtained in accordance with the Helsinki declaration.
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Study design
The remission-induction course (ICE) consisted of idarubicin 10 mg/m2 per day as a five minute iv
injection on days one, three, and five combined with a continuous iv infusion of cytarabine of 100
mg/m2 per day on days one through 10, and one hour iv infusions of etoposide of 100 mg/m2/day on
days one through five. In case of partial response a second identical remission-induction course was
scheduled. The remaining patients were advised to receive as salvage therapy either an allogeneic
transplantation with an HLA-identical donor, if available, or a chemotherapy regimen containing
low dose cytarabine with ATRA. Patients entering a CR after one or two courses of remission
therapy received one consolidation course starting four weeks after the beginning of the (last)
remission-induction course. The consolidation course (IDIA) consisted of two hour iv infusions of
cytarabine 500 mg/m2, every twelve hours for six days, combined with five minutes iv injections of
idarubicin 10 mg/m2 per day on days four through six. Patients without an HLA-identical family
donor received Filgrastim 300 µg sc/day from day 20 after the start of the consolidation course until
completion of the stem cell aphereses.
HLA-typing of patients, parents and siblings was initiated at the onset of induction therapy in all
patients younger than 50 years (or younger than 55-60 years according to the policy of the center).
The patient was proposed for allografting in case of an HLA-A, -B, -DR identical, mixed
lymphocyte culture nonreactive sibling, a one-locus class-I mismatched sibling or a phenotypically
identical parent. The alloSCT was planned as soon as possible after recovery from the consolidation
course. Patients not eligible for alloSCT were randomized to receive autologous stem cell
transplantation or a second consolidation course. The second consolidation course (HiDAC)
consisted of intravenous infusions of 1 g/m2 of cytarabine for two hours every twelve hours for six
consecutive days (12 infusions in total). The transplant conditioning regimens used throughout this
study were based on total body irradiation or busulphan. T cell depletion of the allografts may be
performed according to the ongoing protocols of the centers.
Required clinical investigations
The MDS section of the pathology review committee of the EORTC-LCG centrally assessed pre-
treatment bone marrow and blood smears (co-ordinator: Dr H. Zwierzina). The classification of
MDS and AML was performed according to the criteria of the FAB-working group. One smear of
bone marrow and blood was also reviewed centrally at the time of CR or first relapse. Apart from
the other standard investigations cytogenetic analysis with banding techniques was mandatory prior
to start of chemotherapy.
Definitions
AML evolved from myelodysplasia is defined as secondary AML (AML-MDS). AML after
chemotherapy or radiotherapy is defined as therapy-related AML (t-AML).
Complete remission (CR) is defined as absence of clinical manifestations of leukemia and less than
five % blasts in a normocellular marrow with normal morphology. The peripheral blood neutrophil
count should be at least 1.5 x 109/L, and the platelet count more than 100 x 109/L. Normalization of
cytogenetic abnormalities has not been included in the definition of CR.
Partial remission (PR) is characterized by BM containing <25% blasts, and >50% decrease of blast
percentage from pretherapeutic levels, normal or near-normal blood counts (granulocytes >1.5 x
109/l, platelets >70 x 109/l, hemoglobin >6 mM) and no circulating blast cells. These findings
should last for at least 8 weeks, except for changes induced by subsequent treatment.
Selection of granulocytes, monocytes and T cells from PB and BM
All samples were separated in polymorphic nucleated cells (PMNC, granulocytes) and
mononuclear cells (MNC) using ficoll 1.077 density gradient centrifugation. Granulocytes
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(PMNC) appeared to be more than 95% pure by flow cytometric analysis based on light
scattering properties. If T cell selection was performed, MNC were washed and stained with
monoclonal antibodies for CD19 and CD3 or CD2. Cells were sorted using a flowcytometer
or magnetic beads. T cells were defined as CD3 or CD2 positive, CD19 negative. Monocytes,
if sorted, were defined as CD3 or CD2 and CD19 negative.
Cytogenetic analysis
Karyotyping was performed with standard banding techniques. All karyotypes at diagnosis
were centrally reviewed in Leuven, Belgium by A. Hagemeijer. Karyotyping for CR samples
was only required for patients with aberrations at diagnosis.
Metaphase and interphase FISH analysis was performed on sorted cell fractions, as described
by Kroef et al.144 Probes used in this study were Vysis LSI 7q D7S486 SO/CEP7 SG (for
resp. 7q31 and centromere 7), Vysis LSI 5q ERG-1 SO/D5S23 SG (for resp. 5q31 and
5p15.2), D8Z2 (for centromere 8) and DYZ1 (for centromere Y). Hybridizations were
evaluated visually. The performance of the different laboratories was tested by sending
various coded samples (unknown to the test lab) by the FISH coordination center in Leiden.
Cut-off values (mean +3SD) for false positivity were 3,1% for 5q- (0,0-8,0%); 3,1% for -7
(0,0-5,0%); 2,3% for +8 (0,0-6,0%) and 1,8% for -Y (0,0-7,0%).
HpaII digestion and HUMARA PCR
HUMARA analysis was performed in eight different laboratories based on a common
protocol: digestion of 0.5 µg of DNA was performed for at least 16 hours at 37˚C in a reaction
mixture of 25 µL, containing 25 units of concentrated HpaII in an appropriate reaction buffer.
After digestion, 5µL of this mixture were used for PCR amplification of the HUMARA locus
with the following primers: forward 5’-ccgaggagctttccagaatc-3’, reverse 5’-
tacgatgggcttggggagaa-3’ in a mixture with Taq DNA polymerase, deoxynucleotides and
appropriate buffers in a total volume of 50 µL. Annealing temperatures varied between
laboratories, because of differences in the PCR machines that were used. Various labs
performed the HUMARA PCR with or without the addition of five % DMSO in the reaction
mixture. The maximal amount of PCR cycles was 33. Also the quantification of alleles varied
between laboratories. All methods were based on denaturing acrylamide separation of PCR
products. For quantification, silverstaining, radioactive labeled primers or fluorescent labeled
primers were used with appropriate quantification software. The performance of each
laboratory was tested by sending round a series of 10 coded samples that constituted a
dilution series of DNA of two males into each other by the HUMARA coordination center in
Nijmegen. All results were within 10% of the actual value for all laboratories. In addition, all
polyclonal myeloid diagnosis samples were re-analyzed in Nijmegen with alternative primers
(forward 5’-ccccaggcacccagaggc -3’, reverse 5’-gagaaccatcctcaccctgct -3’), as has been
described previously.33
The efficiency of HpaII digestion was tested for all polyclonal myeloid diagnosis samples by
comparing the amount of a gene that escapes X-chromosome inactivation (XE169) before and
after digestion with real time quantitative PCR as described previously.42 Briefly, quantitative
real-time PCR was performed with the ABI/PRISM 7700 Sequence Detection System
(Applied Biosystems, Foster City, Ca, USA). Primer sequences were: forward: 5’-
gcttggtgtgacgcaacgta-3’, reverse: 5’-gccttcgccaccacagttca-3’. The sequence of the TET-
labelled probe was: 5’-aggacaccccgcggaaggatcc-3’. PCR conditions were as follows: 10 min.
at 95°C followed by 45 cycles of 15 sec at 95°C and 1 min. at 57°C, with data collection in
the last 30 seconds. The reaction mixture for all PCRs contained 1.25 U AmpliTaq Gold, 5µL
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10xbuffer A or 5 µL 10xsybr green buffer, 5 mM MgCl2 (all Applied Biosystems, Foster City,
Ca, USA) and 250 mM dNTPs (Pharmacia, Uppsala, Sweden). Primer concentrations were
900 nM and the probe concentration was 200 nM in a total volume of 50 µL. The reduction of
XE169 copies was calculated by comparing the cycle threshold (Ct) value of two aliquots of
the same sample; both were treated identical with the exception of the presence or absence of
HpaII in the digestion mixture. The reduction was calculated by the formula:
Fold reduction = 2((Ct with HpaII)-(Ct without HpaII)). All PCR analyses were performed in duplicate.
Statistical analyses
All patients were registered prospectively at the EORTC Data Center in Brussels. The duration of
survival was calculated from the date of start of treatment until death, whatever cause. For patients
who achieved CR after induction, the disease-free survival was calculated from the date of first CR
until the date of first relapse or until death in CR. Patients who died in first CR were censored at that
moment for the time-to-relapse analysis and patients who relapsed were censored at that moment for
the “treatment-related mortality”. The duration of survival of remitters corresponds to the time from
first CR to the date of death. The actuarial curves were computed using the Kaplan-Meier
technique,145 and the standard errors (SE) of the estimates were obtained via the Greenwood
formula.145 The differences between cytogenetic responders and non-responders in CR were
analyzed with the χ2-test. The Cox Proportional Hazard Model has been used to determine the
prognostic impact of several factors regarding the DFS and survival from CR, and to obtain
estimates of the hazard ratio (HR) and the corresponding 95% confidence interval. All analyses were
performed according to the intent-to-treat principle.
Results
Patient characteristics at diagnosis and CR
Of 347 patients included in the study, 312 were evaluable for response to the remission
induction and consolidation therapy (analysis of December 2002). A total of 173 patients
reached CR after one or two remission induction courses (55.4%). Fifty-nine patients
remained in continuous CR while the other patients either relapsed (92) or died in CR (22).
The patient characteristics, the results of remission induction therapy and the event free
survival for those who achieved CR are given in Tables 1-3. At diagnosis and at completion
of either induction or consolidation therapy, BM, PB or both was collected for morphological
and molecular analysis. The median survival time was 1.5 years, and the actuarial three-year
survival rate was 31.7% (38.7% at two years). The median actuarial follow-up was 2.9 years.
Cytogenetic analysis at diagnosis
Cytogenetic analysis with standard banding techniques was performed and centrally reviewed
for 265 patients at diagnosis. Patients were stratified according to the IPSS cytogenetic score;
good: no abnormalities, -Y alone, 5q- alone, 20q- alone; poor: complex (three or more
aberrations), chromosome 7 abnormalities; intermediate: all other aberrations. This
stratification resulted in a strong prognostic impact both on survival and on DFS of the
patients who achieved complete remission (p < 0.0001, Figure 1). In univariate analysis, the
cytogenetic score had the strongest impact on survival. Also the IPSS cytopenia score and age
had impact on survival. The IPSS marrow blast score did not predict the survival of this group
of patients. Multivariate analysis showed the IPSS cytogenetic score and age to be
independent variables for the prediction of survival (Table 4).
Only normal metaphases were present in 112 patients (42%, Table 5a). The most frequent
single aberrations were monosomy of chromosome 7 (39 patients), deletion of 5q (38
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Table 1 Characteristics of eligible patients
variable No. (%)
FAB
  RA/RARS 8 (2.6)
  RAEB less than 10% blasts 23 (7.4)
  RAEB 10% blasts or more 74 (23.9)
  RAEBt 112 (36.2)
  CMMoL 20 (6.5)
  sAML 72 (23.3)
Age at start of treatment (years)
  younger than 45 85 (27.2)
  between 45 and 55 104 (33.3)
  55 or older 123 (39.4)
WBC (x 109/L)
  less than 5 183 (58.8)
  5-25 93 (29.9)
  25 or more 35 (11.3)
Cytogenetic examination
  unsuccessfula 47 (15.1)
  successful 265 (84.9)
IPSS classification (MDS only)
  unknown 38 (18.0)
  Intermediate-1 (0.5-1.0 points) 23 (10.9)
  Intermediate-2 (1.5-2.0 points) 75 (35.5)
  High risk (> 2 points) 93 (44.1)
a Less than 10 normal metaphases, less than 3 abnormal metaphases, or no data at all.
Table 2 Results of remission-induction therapy
Courses
I I+II Percentage
Complete remission 157 173 55.4
Partial remission 45 21 6.7
Resistant 63 71 22.8
Persisting hypoplasia 17 17 5.4
Death in hypoplasia 28 28 9.0
Early death 1 1 0.3
Table 3 Event free survival status of patients having achieved CR
status No. (%)
CCR 59 (34.1)
relapse 92 (53.2)
death in CR 22 (12.7)
patients) and trisomy of chromosome 8 (28 patients). Monosomy of chromosome 5 was only
observed in combination with other aberrations (11 patients, all with a complex karyotype).
Deletion of 20q as single aberration was observed in 3 patients while it was frequently
involved in complex karyotypes (eight patients). Other frequent aberrations were deletion of
7q (14 patients), loss of chromosome Y (four patients) and aberrations involving 3q (17
patients): six patients with inversion 3, two with t(2;3), three with t(3;3), two with t(3;5), one
with t(3;12), one with t(3;18) and two with deletion of 3q of which one also with
dup(3)(q21q26). Other balanced translocations (n=18) were observed in 16 patients (table 5b).
These included three patients with t(8;21), one with t(9;11) and one with t(6;9). The
remaining translocations were single cases. Recurrent breakpoints were 2q21 (3x), 12p13 (2x)
and 20q11 (3x). Of interest were also the occurrence of del(11)(q21-24) which was found six
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Table 4 Impact of the IPSS cytogenetic, cytopenia and BM scores and age on survival
hazard ratio 95% confidence
interval
p-value
univariate analysis
IPSS cytogenetic score 1.95 1.61-2.35 <0.0001
IPSS cytopenia score 2.30 1.02-5.186 0.045
age 1.45 1.05-2.00 0.026
IPSS BM blast score 0.95 0.73-1.34 0.70
multivariate analysis
IPSS cytogenetic score 1.98 1.64-2.39 <0.0001
IPSS cytopenia score 2.09 0.92-4.74 0.079
age 1.52 1.10-2.11 0.012
Categories used were: IPSS cytogenetic score: good, intermediate, poor; IPSS cytopenia score: 0 to 1
versus 2 to 3 of the following cytopenias: hemoglobin less than 10 gram/dL or red blood cell
transfusion dependent; platelet count of less than 100 x 109/L or platelet transfusion dependent;
neutrophil counts less than 1.5 x 109/L; age: younger than 55 years or 55 years and older; IPSS BM
blast score: less than 5%; between 5% and 10%; between 11% and 20%; between 21% and 30%.
Table 5a Cytogenetic characteristics at diagnosis according to IPSS cytogenetic score
IPSS cytogenetic score
good intermediate poor (complex)
-Y - 1 4 (3)
+8 - 16 11
-5 - - 10 (10)
-7 - - 33a (18)
5q- 7 3 24 (21)
7q- - - 14b (11)
other 4 35 12 (12)
normal 102 - -
total 112 60 69
a -7 as sole aberration: 12. b 7q- as sole aberration: 3
Table 5b List of balanced translocation not involving 3q
t(8;21)(q22;q22), 3 cases
t(9;11)(p21;q23)
t(6;9)(p23;q34)
t(2;19;6)(q21;p13;p12)
t(2;17)(q21;p13)
t(2;14)(q21;q32)
t(2;15)(q37;q13)
t(2;17)(q35;q12)
t(7;21)(p13:q22)
t(7;12(q34;q13)
t(12;14)(p13;q22)
t(12;22)(p13;q12)
t(1;20(q24;q12)
t(10;20)(q23;q13)
t(17;20)(q12;q11)
t(17;12)(q24;q21)
times and loss of 12p (13x) due to either del(12p) or add(12p). Many unbalanced
translocations were present in the complex karyotypes as well as dicentric derivatives. A
complex karyotype was observed in 66 patients, 57 of which involved aberrations of
chromosomes 5, 7 or 8.
FISH was performed for 163 patients in whom also karyotyping was done. Centromere probes
were used for chromosomes 7, 8 and Y, and locus-specific probes for 5p, 5q and 7q. In 158
patients the karyotype was compatible with the FISH analysis. In 85 patients the FISH and
banding analyses matched completely. In 30 patients the karyotype showed additional
aberrations outside the FISH probes. In 29 cases the karyotype showed only aberrations
outside the FISH probes, which rendered them non-detectable with FISH. In six patients
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additional aberrations were found with FISH that were not detected with karyotyping. As the
additional aberrations were in a minority of cells (15% at most) these samples most likely
contained an additional subclone due to clonal evolution of the malignant cells. In three
patients an additional trisomy of 8 was observed, in two patients an additional deletion of 5,
and in one case an additional deletion of 7q, 5q and loss of Y. In eight patients discrepancies
were observed between FISH and karyotyping. In one patient a deletion of 5q was observed in
more than 90% of cells with FISH and not observed in the karyotype, suggestive of the
presence of a subtle 5q deletion. All other cases were aberrations observed in karyotyping and
not in FISH: i.e. three cases of 7q-, two cases of 5q- (in subclone), one -5 and one -Y.
Possibly the breakpoints on 7q and 5q were misjudged and were present outside of the FISH
probe regions.
Cytogenetics in remission
Of 173 patients in morphological CR, 72 patients showed a cytogenetic aberration at
diagnosis. Cytogenetic analysis was repeated in 46 of these patients by karyotyping. A
complete disappearance of the cytogenetic marker was observed in 32 patients (70%), while
the cytogenetic marker persisted in the other 14 patients. A trend towards a better survival
was observed for patients with a cytogenetic response in CR (p = 0,087, Figure 2). The most
significant difference was the relapse rate between the two groups: 57% in the responder
group and 93% in the non-responder group (p = 0.015). The characteristics of the 46 patients
are given in Table 6a. For six patients both karyotyping and FISH analysis were available at
CR (Table 6b). In all patients a low percentage of aberrant cells detected by FISH
corresponded with no (four patients) or very few (one patient) aberrant cells in the karyotype.
Clonality analysis with HUMARA PCR
The degree of clonality of female samples was investigated by measuring the XCIP with the
HUMARA PCR. The XCIP was expressed as the relative abundance of the larger of the two
HUMARA alleles after PCR amplification. For myeloid cells, the source of the cells (PB or
BM) and the cell type (granulocytes or monocytes) were assessed for their impact on the
XCIP ratio. The degree of clonality was compared between myeloid cells of PB and BM in 44
different samples of 31 patients (Table 7a). A high correlation existed between paired blood
and bone marrow samples (R = 0.97). The mean difference was a 1.2% more skewing in bone
marrow. In three cases the difference was more than 20%. These differences were observed in
granulocytes at diagnosis. In two of these cases the granulocytes from the bone marrow were
more skewed (22% and 23%) and in the third case the granulocytes of the blood had a more
extreme XCIP (21%).
A high correlation was also observed between the XCIP ratios of monocytes and granulocytes
(R = 0.87, Table 7b). A total of 35 samples were compared from 22 different patients. The
mean difference was a 1.6% more skewing of the XCIP in monocytes. In four cases the
difference was more than 20%. In three cases the monocytes showed a more extreme XCIP
(63, 24 and 21%) and in the other case the granulocytes were more skewed (22%). These four
cases were all diagnosis samples. In four cases XCIP ratios were compared in T cells from
blood and bone marrow. The mean difference was 0.75%, ranging from –6% to 7%.
Clonality at diagnosis
A clonal XCIP ratio was defined as a ratio of HUMARA alleles after PCR of 25% or less, or
75% or more. All other ratios were considered non-clonal. At diagnosis, myeloid cells of
patients were clonal in 62 out of 69 patients (90%). In 33 patients, more than one myeloid cell
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Figure 1
Strong impact on survival of the IPSS cytogenetic score in high-risk MDS patients and patients with
AML supervening after MDS.
(a) The survival from start of treatment in years for 265 patients of whom the karyotype was known at
time of diagnosis, stratified according to the IPSS cytogenetic score. All three groups were statistically
different; overall log rank test, p < 0.0001. (b) The disease-free survival in years from the
achievement of complete remission for 141 patients of whom the karyotype was known at time of
diagnosis, stratified according to the IPSS cytogenetic score. All three groups were statistically
different; overall log rank test, p < 0.0001.
population was analyzed (granulocytes and/or monocytes in BM and/or PB). Of those, 24
patients showed a clonal XCIP in all cell populations, while in eight patients the granulocytes
of the blood were non-clonal with a clonal XCIP in one or more other myeloid cell
populations. Additionally, one patient had non-clonal PB monocytes while the other myeloid
cells were clonal. Also these nine samples were considered clonal. A non-clonal XCIP was
observed in seven patients (10%), of whom only one myeloid cell population was available.
Of those, five samples were granulocytes (two PB, three BM) and two were monocytes (one
PB and one BM). The survival was not different for patients with clonal or non-clonal
myelopoiesis at diagnosis (p = 0.15, Figure 3). Although the hazard ratio was 1.89 for patients
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Figure 2
A worse disease-free survival for patients with persisting cytogenetic abnormalities in CR.
The disease-free survival (DFS) in years from achievement of CR is compared between patients with a
complete disappearance of cytogenetic abnormalities and patients with persistence of cytogenetic
abnormalities in one or more metaphases either after remission induction or after consolidation
treatment. All patients had a cytogenetic abnormality at diagnosis. The patients with persisting
abnormalities tended to have a significant worse DFS (p = 0.087).
Table 6a Characteristics of patients with or without cytogenetic response in clinical CR
non-responders (14) responders (32) p-value
IPSS cytogenetic score NS
     good 1 (7%) 2 (6%) NS
     intermediate 4 (29%) 15 (47%) NS
     poor 9 (64%) 15 (47%) NS
time of evaluation
     after remission induction 11 (79%) 27 (84%) NS
     after consolidation 3 (21%) 5 (16%) NS
median follow-up (days) 189 238 NS
status 0.049
     CCR 1 (7%) 11 (34%) 0.053
     relapse 13 (93%) 18 (57%) 0.015a
     TRM 0 (0%) 3 (9%) NS
NS, not significant (p>0.1). CCR, continuous CR. TRM, treatment related mortality. a p = 0.037 when
only patients were analyzed with cytogenetic examination after remission induction therapy.
Table 6b Comparison of karyotyping and FISH in CR
pat ID karyotype CR
(positive/total cells)
FISH CR
(%positive cellsa)
status
6 -7, +8 (2/32) -7 (3.8%) +8 (7.6%) relapse
11 †normalb -7 (5%) relapse
28 normal -7 (6.0%) TRM
77 normal +8 (1.3%) relapse
122 normal -7 (1.5%) relapse
200 normal -5 (5%) -7 (3%) relapse
TRM, treatment related mortality. a >100 cells were counted. b for a karyotype to be considered
normal, at least 10 cells had to be counted.
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with non-clonal myelopoiesis, the 95% confidence interval was very large (0.79 - 4.53) due to
the small number of patients with non-clonal myelopoiesis.
Incomplete digestion of the active X-chromosome yields a polyclonal background in a
monoclonal sample after HUMARA PCR. We therefore checked the digestion of the DNA of
these samples by comparing the amount of copies of a gene that escapes X-chromosome
inactivation (XE169) before and after HpaII digestion with real time quantitative PCR. The
average efficiency of digestion in these samples was 99.8% since the average reduction of
XE169 DNA after digestion was 475-fold (ranging from 20- to 2000-fold). This ruled out that
inefficient HpaII digestion caused the non-clonal XCIP in these patients. Inadequate HpaII
digestion of DNA of granulocytes was found in two patients with a non-clonal XCIP in the
granulocytes but a clonal one in the monocytes as described before.42
Both T cells and myeloid cells were available for XCIP analysis in 61 female patients (Figure
4). In contrast to the myeloid cells, only 31% of the T cells showed a clonal XCIP. The mean
difference between the XCIP ratio of T cells and myeloid cells was 24%, ranging from 63%
more skewing in myeloid cells to 18% more skewing in T cells. In four cases skewing of the
XCIP in T cells was in the opposite direction as the skewing in myeloid cells, indicating a
general skewing of hematopoiesis (T cell XCIP) with a clonal expansion of myeloid cells
arising from a cell with the least predominant XCIP. The IPSS cytogenetic scores for the
patients with a clonal T cell XCIP were similar to those of the entire patient population (nine
good, three intermediate, five poor).
Cytogenetic analysis by karyotyping was available for four of the seven ‘non-clonal’ patients.
Two patients had a good IPSS cytogenetic score (no abnormalities and 5q-) and two had a
poor IPS cytogenetic score (-7 and complex with +8 and 5q-). The IPSS cytogenetic scores
for the ‘clonal’ patients were not different from the entire patient population. Both FISH and
clonality analysis were performed in 14 cases. In three cases a minor FISH clone was detected
(35% or less positive cells) while the XCIP was extremely skewed (more than 85% of either
HUMARA allele). In nine cases the percentages were compatible. In two patients a
polyclonal XCIP pattern with complete digestibility of DNA as shown by XE169 analysis
was present while more than 90% aberrant cells were observed with FISH. As no more
material was available for these patients to repeat both analyses these samples have been
excluded from the analysis.
Clonality in remission
Patients in morphological complete remission (CR) could be evaluated for clonality in 22
cases. A response in clonality was defined as a reduction of the XCIP ratio by 20% or more,
as the margin of error for the XCIP ratio measured by HUMARA PCR is 10%. Twelve
patients showed a response in clonality (57%) while nine patients did not (Figure 5). The
mean response in XCIP ratio in the responder group was 34%, ranging from 20% to 59%. The
mean difference between XCIP ratios at diagnosis and CR for the non-responder group was
four %, ranging from seven % more skewing to 18% less skewing.
T cell data were available for 16 patients in CR. No differences of more than 20% were
observed between diagnosis and CR samples. The mean difference was 1.3% less skewing of
the T cell XCIP at CR, ranging from 11% more skewing to 13% less skewing. T cell data
were available for seven of the XCIP non-responders. A significant difference between T cells
and myeloid cells was observed in only one of these patients, indicating that in the other
patients a biologically skewed XCIP in hematopoiesis may mask a molecular response to
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Figure 3
No difference in survival for patients with non-clonal or clonal myelopoiesis at diagnosis.
The survival from start of treatment in years is compared between patients, evaluable for response,
with clonal and patients with non-clonal myelopoiesis at diagnosis. The hazard ratio for non-clonal
patients was 1.89 (0.79-4.53), p=0.15
Table 7a The comparison of XCIP ratios of myeloid cells in PB and BM
cell type sample N BM vs PBa range Rb
granulocytes diagnosis 22 4.5 -21, 23 0.96
,, CR 12 -1.6 -15, 6 0.97
,, 6 months post treatment 3 -0.3 -1, 1
,, 12 months post treatment 1 -7
monocytes diagnosis 4 -3.5 -12, 3
,, CR 2 -0.5 -2, 1
all samples 44 1.27 -21, 23 0.97
a the mean difference in the XCIP ratio (%) between BM and PB; a positive value means that the BM
had a more extreme XCIP ratio. b Pearson correlation coefficient
Table 7b The comparison of XCIP ratios in granulocytes and monocytes
cell type 1 cell type 2 sample N differencea range Rb
granulocytes PB monocytes PB diagnosis 19 5.05 -22, 62 0.86
,, ,, CR 6 -0.83 -12, 9
,, ,, 6 months PT 2 -3.5 -4, -3
,, ,, 6 months PT 1 -8
granulocytes BM monocytes BM diagnosis 3 -9.76 -18, -5
,, ,, 6 months PT 2 -0.5 -2, 1
,, monocytes PB 6 months PT 2 4.5 -4, 13
all samples 35 1.6 -22, 62 0.87
PT = post treatment. a the mean difference in the XCIP ratio (%) between monocytes and
granulocytes; a positive value means that the monocytes had a more extreme XCIP ratio. b Pearson
correlation coefficient
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treatment. This was exemplified in one patient of whom multiple samples were available for
XCIP analysis (Fig 6a). No fluctuation in XCIP ratio of more than 20% was observed in any
of the four samples, neither for myeloid cells, nor for T cells. However, this patient did show
a cytogenetic response in CR (complete disappearance of –7, both with standard karyotyping
and FISH). Multiple samples were also available for one of the cases with skewing of the
XCIP in opposite directions in T cells and myeloid cells at diagnosis. The remission sample
showed similar XCIP ratios for the T cells and the myeloid cells, which was the same XCIP
as for the T cells at diagnosis (Figure 6b). This confirmed a general skewing of hematopoiesis
(T cell XCIP) with a clonal expansion of myeloid cells arising from a cell with the least
predominant XCIP.
For three more patients in CR both clonality and cytogenetic analyses were available. One of
the two patients with a response in clonality also showed a complete cytogenetic response
while the other showed persisting abnormalities (+13, +14, +21) in seven out of eight mitoses.
The last patient showed persisting clonal cells with both techniques. Clinical follow-up was
available for 10 patients of the XCIP responders and 9 patients of the non-responders. No
statistical difference was observed in the DFS from CR for the XCIP responders and non-
responders (p=0.91).
Discussion
We evaluated the molecular status of high-risk MDS patients and patients with AML
supervening after MDS before and after intensive antileukemic treatment. A morphological
CR was achieved in 173 of 312 patients evaluable for response (55%). Of patients in CR, a
complete cytogenetic remission was observed in 32 out of 46 patients with a cytogenetic
aberration at diagnosis (70%). This group of patients had a lower relapse rate (p = 0.015) and
tended to have had a better DFS than the group with persisting abnormalities (p = 0,087).
Clonality analysis by determination of XCIP showed a response in 12 out of 21 patients
(57%).
FISH seems to be the obvious choice for analysis of patients in morphological CR when
compared to karyotyping. As karyotyping involves cell culture, both over- and
underestimation of the residual tumor load may result, depending whether the nature of the
aberrations confers a growth advantage or inhibition to the malignant cells. This drawback
does not interfere with FISH, as no cell culture is involved. However, background signals in
FISH (generally around five %, depending on the probe) may vary between samples, making
interpretation of percentages between five and 10% difficult. Sorting of progenitor cells
before the analysis could increase sensitivity of cytogenetic analysis by FISH. Confirming
this, Engel et al. showed that only one of 12 MDS patients who achieved CR after
chemotherapy was in cytogenetic remission when progenitor cells were investigated with
FISH.49 Interestingly, the authors found that in two cases residual abnormal cells could only
be detected after sorting and that the load of abnormal cells in the sorted BM progenitor cells
was two- to threefold higher than in the unfractionated BM. In a previous study investigating
the cytogenetic response to treatment of overall BM a response was observed in eight out of
33 MDS patients (24%) who received either low-dose cytarabine or palliative treatment.48
We found a significant reduction of clonal cells after treatment in 57% of patients (12 out of
21). Analysis of X-chromosome inactivation patterns in females is an alternative method for
the evaluation of a molecular response to treatment in patients who do not have cytogenetic
abnormalities at diagnosis. In this study a normal karyotype was present in 16 of the 21
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Figure 4
Seventy-four % of patients show clonal myeloid cells with non-clonal T cells at diagnosis.
Plotted is the X-chromosome inactivation pattern (XCIP), expressed as the relative abundance of the
larger of HUMARA alleles after HpaII digestion followed by PCR amplification, for the myeloid cells
of 69 patients. Paired T cell ratios are given for 60 patients. Non-clonal samples were defined as
having a ratio between 25 and 75%, more extreme ratios were defined as clonal. All data are the
means of duplicates.
patients analyzed for a response in XCIP. Major assets of this technique are the correlation
between clonility and the first hit in the MDS clone and that ~90% of (female) patients can be
investigated, irrespective of the presence of cytogenetic abnormalities and other prognostic
factors. However, the interpretation of the response in clonality is hampered by biological
skewing of hematopoiesis towards one of the X-chromosomes and the low sensitivity of the
technique. Acquired skewing of Lyonization in hematopoietic cells occurs gradually during
life and may be as high as 40% of the female population over 60 years of age.26,27 Although
the incidence is lower in younger individuals, acquired skewing of Lyonization may mask a
response to treatment in patients who do not show a response in clonality. Using the T cell
XCIP as a control for biological skewing of the XCIP may also not be entirely satisfactory, as
skewing of myelopoiesis with a non-skewed T cell pattern has been described to occur in a
minority of healthy individuals.27,28,33 A response towards polyclonality of more than 20%
will always represent a response to treatment. However, the margin of error for the XCIP as
determined by HUMARA PCR is approximately 10%.16 This means that a sample with a
fully balanced XCIP in CR may still harbor 20% of clonal cells, indicating a lower sensitivity
for the detection of clonal cells with XCIP determination compared to cytogenetic analysis
(~10%). The response of clonality in CR had no predictive value in this study, probably
resulting from a combination of low sensitivity, the presence of biological skewing of XCIP
and the limited number of patient samples available for clonality analysis. In a previous study,
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Figure 5
Achievement of CR is accompanied by a response in clonality in 57% of patients.
Plotted is the X-chromosome inactivation pattern (XCIP), expressed as the relative abundance of the
larger of HUMARA alleles after HpaII digestion followed by PCR amplification, for the myeloid cells
of 21 patients at diagnosis and in CR. Closed circles: non-responders (response less than 20%); open
circles: responders (more than 20%). All points are the means of duplicates.
a response in clonality of myelopoiesis of more than 20% was observed in 2 out of 6 patients
after intensive antileukemic treatment.47 In another small study, long-term remission of MDS
patients was generally associated with polyclonal hematopoiesis (5 out of 6 patients).50
In the present study the cytogenetic score was found to be the most important predictive
parameter for the survival of high-risk MDS patients, having a higher impact than the number
of cytopenias, age, and marrow blast percentages. We showed that the degree of clonality in
MDS is similar in granulocytes and monocytes. Also the clonality of myeloid cells from PB
and BM showed a similar pattern. We confirmed that the majority of patients have clonal
myelopoiesis at diagnosis.39,40 However, a small subgroup of patients showed non-clonal
myelopoiesis. The significance of this finding remains unclear, both for the survival of
patients and for the occurrence of cytogenetic abnormalities in these patients. When more
than one myeloid cell population was examined at least one of those was clonal in all patients.
This suggests that clonal myelopoiesis is predominant in most if not all high-risk MDS
patients, although residual polyclonal myelopoiesis may occur in some patients. A possible
difference in the survival of such patients needs to be examined in a larger study.
Intensive antileukemic treatment followed by allogeneic or autologous BM transplantation
has been shown beneficial to high-risk MDS patients and patients with AML after MDS. CR
can be achieved in 50% to 64%11,139,142,143 of the patients while the four-year disease free
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Figure 6
XCIP ratio in time for two patients
(a) No difference of more than 20% in either myeloid cells or T cells. This MDS patient showed a
complete disappearance of a complex karyotype in CR, indicating that in this patient skewed
hematopoiesis might mask a clonal response to treatment. (b) Skewed hematopoiesis in a sAML
patient in whom the malignant clone originated from a cell with a different XCIP than the majority of
cells. In CR both myeloid and T cells show the same polyclonal, skewed XCIP. For both patients the
3rd and 4th sample were obtained 6 and 12 months after the completion of treatment.
survival rates are close to 30%.139,146 In the present study CR rates and disease free survival
were similar with previous studies (55.4% and 31.7% respectively).
We conclude that a morphological CR after antileukemic treatment of high-risk MDS patients
is accompanied by a molecular response in more than half of the patients (70% for
cytogenetic response and 57% for an improvement of XCIP ratio). The persistence of
cytogenetic aberrations in clinical CR is likely to identify a group of patients with a worse
prognosis and a need for alternative treatment in investigational protocols. Analysis with
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Figure 7
Disease-free survival in years from achievement of CR for patients with or without a clonal
response in CR.
The disease-free survival was not different between the two groups (p = 0.91).
FISH on sorted progenitor cells may provide additional information for patients in a
cytogenetic remission. The impact of clonality at diagnosis needs further investigation. The
analysis of clonality in CR is too much hampered by biological skewing and insensitivity of
the technique to be of predictive value.
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Abstract
In normal bone marrow, WT1 expression is restricted to CD34+ cells. We assessed WT1
mRNA expression levels with quantitative, real-time RT PCR in normal, myelodysplastic
(MDS) and secondary acute myeloid leukemia (sAML) bone marrow subfractions based on
differentiation status. The highest WT1 expression was observed in the primitive CD34+
rhodamine-123 (rho) dull cells both in healthy donors and MDS or sAML patients. In contrast
to normal CD34-negative bone marrow cells WT1 was present in CD34-negative bone
marrow cells of 12 out of 13 MDS patients and 2 sAML samples. Further analysis of this
aberrant WT1 expression was performed in CD34-negative subfractions of 3 MDS patients.
In one of these, WT1 expression was found exclusively in the erythroid cells. This patient was
completely transfusion dependent and showed morphological dyserythropoiesis. In another
MDS patient, WT1 expression was found in a non-erythroid compartment. We conclude that
abnormal WT1 expression may contribute to the disturbed differentiation of hematopoietic
cells in MDS patients.
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Introduction
The WT1 gene has been implicated in the development of Wilms’ tumor, a pediatric kidney
cancer.66,67 The gene encodes a protein that acts as a transcription factor but may also play a
role in posttranscriptional modification (for a recent review see Menke et al).68 Alternative
splicing results in four biologically distinct proteins.69,70 In various malignancies a role for
WT1 has been proposed, either through point mutations (Wilms’ tumor, leukemia71-74),
translocations (desmoplastic round cell tumor75), or aberrant expression (mesothelioma,
leukemia, breast carcinoma76-78). Mice with homozygous null mutations are not viable, lack
kidneys, gonads and adrenal glands, and show defective formation of the heart and spleen.79-
81
 Recently, distinct functions were shown in mice for the splice variants with or without an
insertion of three amino acids (KTS) between the third and fourth zinc finger.82 Mice with a
reduced level or absence of either WT1 isoform presented with severe kidney defects.
In normal hematopoiesis, WT1 expression has been found in primitive CD34-positive BM
blasts, decreased during differentiation and was not detectable in mature blood cells.83,84 The
fact that mutations in WT1 occur in approximately 10% of AML cases is a strong indication
for involvement of WT1 in leukemia.73,74 Furthermore, in AML a high WT1 expression has
been shown in the overall BM of about 90% of patients. High WT1 expression has also been
found in acute lymphoblastic leukemia, chronic myeloid leukemia in blast crisis and in
advanced cases of MDS, such as refractory anaemia with excess of blasts (RAEB) and RAEB
in transformation (RAEBt) (recently reviewed by Chen).87 Whether WT1 expression in
leukemic blasts is aberrantly high or not remains controversial. One study showed a 10-fold
higher expression of WT1 in leukemic cells compared to normal primitive BM cells.60 On the
other hand, two other groups did not observe significant differences in WT1 expression
between AML blasts and normal CD34+ progenitors.61,88 The importance of WT1
downregulation for differentiation has been shown in studies in which constitutive WT1
expression blocks differentiation upon stimulation with various agents, both in leukemic cell
lines and in normal myeloid progenitor cells.93,95,147,148
In order to gain more insight in WT1 expression during differentiation in malignant
hematopoiesis, we measured WT1 expression in cells with various differentiation markers in
MDS. MDS is a clonal BM disease that is characterized by disturbed maturation of myeloid
and erythroid lineages, but in which also functional differentiation still occurs. WT1
expression in MDS was compared with MDS samples that showed progression to sAML and
normal BM. We determined WT1 mRNA levels with a real-time quantitative reverse
transcription polymerase chain reaction (RT-PCR) method. BM CD34+ cells were sorted,
based on rhodamine-123 (rho) retention, into more primitive (rho dull) or less primitive (rho
bright) cells.149,150 The CD34-negative population in a number of patients and donors was
subfractionated, according to the expression of various differentiation markers.
Materials & methods
Patient and donor samples
A total of 23 BM samples from 14 MDS patients and 6 healthy donors was analysed. Patient
characteristics are given in Table 1. All patient samples were obtained after informed consent.
Bone marrow mononuclear cells were cryopreserved in liquid nitrogen after Ficoll 1.077
density gradient centrifugation.
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Cell sorting
After thawing, cells were washed and incubated with one or more of the following murine
monoclonal antibodies: CD34-PC5, IgG1; CD34-PE, IgG1; CD3-FITC, IgG1; CD15-PE,
IgM; CD33-PC5, IgG1; CD41-PE, IgG1 (Coulter-Immunotech, Marseille, France); CD19-
FITC, IgG1; CD14-PE, IgG2; CD33-PE, IgG1 (DAKO, Glostrup, Denmark); CD15-FITC,
IgM (Becton Dickinson, San Jose, CA, USA); CD36-FITC (CLB, Amsterdam, the
Netherlands). All incubations were performed for 20 minutes at room temperature with 5 µL
of each antibody per 1x106 cells per mL Hanks balanced salt solution (HBSS) with 1% bovine
serum albumin (BSA). Cells were washed and sorted on a Coulter Epics Elite flow cytometer
(Beckman Coulter, Fullerton, CA, USA). After sorting, cells were prepared for RNA
isolation, or used for a second antibody staining. Rhodamine retention was assayed as
described earlier.150 Briefly: CD34-positive cells were incubated in Iscove’s medium with 10
% fetal calf serum (FCS) and 1 µg/mL rhodamine-123 (rho) (Sigma, St Louis, MO, USA) at
37°C for one hour. After washing the cells were incubated with rho-free medium for one hour
at 37°C. After sorting into rho dull and rho bright fractions the cells were prepared for RNA
isolation.
RNA isolation and cDNA reaction
RNA isolation was performed as described earlier with minor modifications.151 Briefly, after
centrifugation cells were lysed with guanidiniumisothiocyanate, RNA was extracted with
phenol/chloroform, precipitated with isopropanol twice in the presence of yeast tRNA,
washed with 70% ethanol and re-dissolved in diethylpyrocarbonate (DEPC)-treated water.
Reverse transcription was performed with 5 to 10 µL of RNA solution depending on the
amount of cells used for RNA isolation in a total mixture of 20 µL, containing 50 mM Tris-
HCl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 10 mM dithiothreitol (DTT), 625 mM dNTPs, 5
mM random hexamers (Pharmacia, Uppsala, Sweden), 20 U RNAsin (Promega, Madison, Wi,
USA) and 200 U Mo-MLV reverse transcriptase (Life Technologies, Gaithersburg, Md,
USA). This reaction mixture was incubated at 20°C for 10 min., at 42°C for 45 min. and at
95°C for 10 min.
Quantitative PCR
Quantitative PCR was performed with the ABI/PRISM 7700 Sequence Detection System
(ABI/PE, Foster City, Ca, USA). Primer and probe sequences for the reference gene PBGD
and WT1 are given in Table 2. rRNA primers and probe were obtained from the 18S rRNA
kit (Perkin Elmer/Applied Biosystems, Foster City, Ca, USA) and used according to the
manufacturer’s instructions. PCR conditions were as follows: 10 min. 95°C followed by 45
cycles of 15 sec 95°C and 1 min. 62°C, with data collection in the last 30 seconds. For all
PCRs 1.25 U AmpliTaq Gold, 1 x bufferA (both Perkin Elmer/Applied Biosystems, Foster
City, Ca, USA), 250 mM dNTPs (Pharmacia, Uppsala, Sweden) and 5 mM MgCl2 were used
in the reaction mixture. Primer concentrations for the PBGD and WT1 PCRs were 300 nM
and 25 nM for the 18S rRNA PCR. All PCRs were performed in a total volume of 50 µL.
Quantification of the PCR signals was performed by comparing the cycle threshold values
(Ct), in duplicate, of each sample with the Cts of a dilution series of K562 cDNA in water.
For normalization, two reference genes were tested; the low-expressed housekeeping gene
PBGD and the highly abundant 18S rRNA. For two donor and three patients samples PBGD
and 18S rRNA signals were compared between equal amounts of sorted CD34+ rho dull and
CD34+ rho bright cells. PBGD expression was significantly lower in the rho dull cells than in
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Table 1 Patient characteristics
UPN sample BM blasts (%) diagnosis interval between
samples (months)
1 1 20 RAEBt
2 51 AML M2 2
2 1 5 RAEB
3 1 5 RAEB
2 8 RAEB 2
4 1 3 RA
5 1 3 RA
6 1 5 RAEB
2 60 sAML 18
7 1 7 CMML
8 1 3 RA
9 1 10 RAEB
10 1 4 CMML
11 1 14 RAEB
12 1 11 RAEB
13 1 14 RAEBt
14 1 9 RAEB
Table 2 primers and probes for PBGD and WT1 PCRs
PBGD forward primer 5’-ggcaatgcggctgcaa-3’
PBGD reverse primer 5’-gggtacccacgcgaatcac-3’
PBGD probe (VIC-labelled) 5’-catctttgggctgttttcttccgcc-3’
WT1 forward primer 5’-cgctattcgcaatcagggtta-3’
WT1 reverse primer 5’-gggcgtgtgaccgtagct-3’
WT1 probe (TET-labelled) 5’-agcacggtcaccttcgacggga-3’
the rho bright cells (mean: 0.36 fold). 18S rRNA was not significantly different between the
two populations (mean rho dull/rho bright was 0.81). Therefore, we used 18S rRNA as
reference gene in all experiments. The detection limit for the WT1, PBGD and 18S rRNA
PCRs was 2.5x10-3 ng K562 cDNA. The ratio of WT1 to PBGD or 18S rRNA in K562 was
defined as 1. Efficiencies (E) for all PCRs were determined from a serial dilution series of
K562 cDNA in water; PBGD, E=1.90; WT1, E=1.89; 18S rRNA, E=1.87, all expressed as the
fold increase in fluorescence per PCR cycle. The correlation coefficients (R2) for the PCR
dilution series were: 0.9998 (PBGD); 0.992 (WT1) and 1.000 (18S rRNA).
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Figure 1
No correlation between the percentage of BM blasts and WT1 expression.
WT1 expression in overall BM of MDS patients is plotted against the percentage of BM blasts. WT1
expression in K562 cells, normalized for 18S rRNA, was defined as 1.0. All points are the means of
duplicates.
Results
Quantification of WT1 expression
In BM mononuclear cells, the WT1 expression was higher in all MDS samples than in normal
healthy BM, ranging from threefold to > 100-fold higher expression. In 14 BM samples from
13 MDS patients the WT1 expression ranged from 1.2 to 0.026 times the WT1 expression in
K562, while in normal BM the WT1 expression was less than 0.01-fold K562. In Figure 1 the
WT1 expression in BM mononuclear cells of each patient is plotted against the percentage of
blasts present in the BM. No correlation was found between the WT1 expression and the blast
count (Pearson correlation coefficient = 0.39). In two cases of AML after MDS (sAML) the
WT1 expression was close to the highest expression seen in MDS (0.52- and 0.48-fold K562).
WT1 expression was compared in BM cells at different stages of maturation between 13
MDS patients and six healthy donors. In donors, a decrease in WT1 expression correlated
with more mature cells: expression was highest in CD34+ rho dull cells, on average fivefold
lower in CD34+ rho bright cells and negative in CD34-negative cells (Figure 2a). In MDS
patients the pattern of WT1 expression was more heterogeneous (Figure 2 b and c). WT1
expression in the CD34+ rho dull cells was similar in most patients and donors. The median
WT1 expression was twofold higher in patients compared to donors (0.38- and 0.19-fold
K562 respectively, p=0.09). A high WT1 expression was seen in two cases (UPN7, chronic
myeloid monocytic leukemia (CMMoL) and UPN9, RAEB). In the CD34+ rho bright cells
there was a trend towards a higher WT1 expression in MDS patients. The median WT1
expression was three times higher in patients compared with donors (0.16- versus 0.05-fold
K562, p=0.03). A clearly abnormal expression of WT1 was observed in CD34-negative BM
cells in 12 of 13 MDS patients. The WT1 expression ranged from 0.002-fold K562 to 0.28-
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Figure 2
WT1 expression during differentiation.
WT1 expression levels are given for three different BM subfractions, ranging from primitive (CD34+,
rho dull) to mature (CD34-). (a) A decrease of WT1 expression is observed in normal BM along with
differentiation. (b) Abnormal WT1 expression is predominantly present in the CD34-negative BM cells
of 10 MDS patients. (c) The expression pattern does not alter after disease progression in three MDS
patients. WT1 expression in K562 cells, normalized for 18S rRNA, was defined as 1.0. All points are
the means of duplicates.   
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fold K562 in MDS patients, while in healthy BM the WT1 expression was negative (less than
0.001-fold K562) in the CD34-negative cells. Resorting of selected CD34-negative cells of
UPN8 showed 99% purity.
Follow-up samples of three patients were evaluated to study WT1 expression over time. Two
samples of one patient were available during stable RAEB, with 5% blasts in the first and 8%
blasts in the second BM sample, 2 months later (UPN 3). Samples of two other patients were
available before and after progression to AML (UPN 1 and 6). UPN 6 progressed from RAEB
(5% blasts) to AML (60% blasts) in 18 months, while UPN 1 progressed from RAEBt (20%
blasts) to AML (51% blasts) in 2 months. In all three patients the WT1 expression pattern did
not change significantly during follow-up (Figure 2c), which argues against a role for WT1 in
disease progression.
WT1 expression in CD34-negative subfractions
To further define the aberrant WT1 expression in the CD34-negative cells of MDS patients,
additional cell sorting was performed. Initially, the WT1-positive CD34-negative BM cells of
three MDS patients were subfractionated, according to the expression of differentiation
markers for lymphoid (CD3, CD19), myeloid (CD33, CD14, CD15), erythroid (CD36) and
megakaryocytic (CD41) cells. Both WT1 -positive and -negative subfractions were observed
in all three patients.
In patient UPN8, myeloid and lymphoid cells were WT1 negative, but WT1 expression was
present in the erythroid cells. This patient was completely transfusion dependent,
demonstrating the inability of erythroid precursors to mature to functional erythrocytes. WT1
expression in the erythroid cells was 0.026 and 0.030 (fold K562) in two independent sorting
experiments. Morphological examination of this cell population showed extensive
dyserythropoiesis, with megaloid nuclei in most cells and disturbed hemoglobinization in
some cells (Figure 3). Erythropoiesis was not left-shifted as the percentage of pro-
erythroblasts was similar to normal values (3%). Also in patient UPN4, the myeloid and
lymphoid fractions were WT1-negative, with the remainder of the cells showing WT1
expression. This patient was also completely transfusion dependent. Although the erythroid
cells of this patient were not sorted, the WT1-positive, CD34-negative cell fraction contained
at least 60% erythroid precursors, based on the overall BM morphology. In patient UPN6, the
erythroid and lymphoid cells were WT1-negative, with the remainder of the cells expressing
WT1. Interestingly, this patient was not transfusion dependent.
The only patient that did not show WT1 expression in the overall CD34-negative BM cells
was also checked for WT1 expression in CD34-negative subfractions. No WT1 expression
was detectable in any of the CD34-negative subfractions, as was the case in two healthy
donors In contrast, when a sAML patient (UPN1, sample 2) was analysed, all CD34-negative
subfractions showed WT1 expression. The expression in the cells with a lymphoid phenotype
was threefold lower than in those with a myeloid or erythroid phenotype. The phenotype,
WT1 expression and relative abundance of the sorted cell populations of all patients and
donors are given in Table 3.
Discussion
In this study, we found that the majority (12/13) of MDS patients had an abnormally high
WT1 mRNA expression in their CD34-negative BM cells. The high WT1 expression in
CD34-negative cells was the main cause for the elevated WT1 levels in the overall BM of
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Table 3 WT1 expressiona and relative abundanceb in MDS BM subfractions
overall lymphoid CD34- myeloid CD34- erythroid CD34-
CD34- CD3+or CD19+ CD14+or CD15+ CD3-19-14-15-
CD33+
CD3-19-14-15-41-
CD36+
MDS, UPN 4 0.088 neg (18) neg (16) NS NS
MDS, UPN 6,
sample 1
0.039 neg (21) NS NS neg (24)
MDS, UPN 8 0.0039 neg (30) neg (34) neg (8) 0.028 (19)c
MDS, UPN 5 neg neg (5) neg (64) neg (5) neg (8)
sAML, UPN 1,
sample 2
0.33 0.15 (9) 0.45 (19) NS 0.40 (63)
donor (2x) neg neg neg NS neg
NS = not sorted
a WT1 expression in K562 cells, normalized for 18S rRNA, was defined as 1.0
b The relative abundance of each fraction is given between brackets as the percentage of the overall
CD34-negative BM fraction
c Average of two independent sorting experiments. WT1 expression and relative abundance of the
cells were 0,026 and 0,030 (fold K562) and 17 and 20% respectively.
these patients. We found WT1 expression in the CD34-negative cells in 12 of 13 MDS
patients while WT1 expression was absent in CD34-negative cells in 6 healthy donors. The
WT1 expression pattern in CD34-negative cells was analysed in more detail in three MDS
patients. In two patients abnormal WT1 expression coincided with complete transfusion
dependency. In one of these, sorted erythroid precursors with abnormal WT1 expression
showed morphological dyserythropoiesis. As erythropoiesis was not left-shifted in this
patient, it is unlikely that the abnormal WT1 expression resulted from an expansion of
primitive erythroid cells that might express WT1 in healthy BM. In another patient who was
not transfusion dependent, abnormal WT1 expression was not present in erythroid cells or
lymphoid cells but in another CD34-negative subfraction. Lymphoid cells were WT1-
negative in all three patients. The use 18S rRNA as a normalization control for quantitative
PCR proved accurate as there was only a small variation in the WT1 expression in the
primitive cells of healthy donors, and the primitive cells of patients at different stages of
disease.
Our results suggest that aberrantly persistent WT1 expression may impair the normal
development of hematopoietic cells. Several studies support a role for WT1 in the
differentiation in hematopoiesis (reviewed by Menke et al).89 In healthy BM, the level of
WT1 expression dropped beyond detection during differentiation.83,84 In the human leukemic
cell lines HL 60 and U937, differentiation induction could be wholly or partially blocked by
ectopic WT1 expression.90,91 In the K562 cell line, different groups found either no effect or a
delay in the inducible differentiation upon WT1 overexpression.92,93 Ectopic WT1 expression
caused a complete or partial differentiation block also in murine 32D cells and in murine
primary BM cells.94,95 In the M1 murine leukemia cell line forced expression of the WT1
induced differentiation.96 These cells also showed a decrease in tumorigenicity when injected
in C.B.-17 scid/scid mice.97 Retroviral transduction of primary human CD34+ cells resulted in
enhanced differentiation of the more mature progenitors and an increase in primitive,
quiescent CD34+CD38- cells.98 The development of mouse models in which the expression of
WT1 can be inactivated or activated in specific cell lineages will be important in attempts to
unravel the function of WT1 in hematopoiesis.
Little is known about the regulation of WT1 expression in hematopoietic cells. A
hematopoietic specific enhancer has been identified in the WT1 gene that can be activated by
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Figure 3
Dysplastic erythroid cells in WT1-positive, CD36+ BM cells.
The immunephenotype of this WT1 positive BM fraction of UPN8 was CD36 positive and
CD34/CD33/CD14/CD15/CD3/CD19/CD41 negative. A May Grünwald-Giemsa staining showed
dyserythropoiesis. This figure shows a normoblast (A) and basophilic erythroblast (B), both with a
megaloid nucleus.
interactions with c-myb or GATA1.152 Deregulation of either gene could therefore result in
altered WT1 expression. When GATA1 and WT1 co-expression were investigated in MDS,
no correlation was found.153 The c-myb gene, like WT1, is expressed in primitive normal BM
and absent in mature cells.154 A high c-myb expression is also found in acute leukemias,155
but a correlation with WT1 expression has not yet been investigated. As c-myb has also been
shown to be a target gene for down-regulation by WT1, it is interesting to speculate that c-
myb and WT1 participate in a feedback mechanism, the disturbance of which may be
involved in abnormal differentiation.
We conclude that abnormal WT1 expression was present in CD34-negative cells in the
majority of MDS patients. This abnormal WT1 expression may be an important factor in the
disturbed differentiation of the myelodysplastic clone. The correlation between WT1
expression and abnormal maturation warrants further investigation into WT1 function in both
normal and malignant hematopoiesis.
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Summary
This thesis describes molecular studies of myelodysplastic syndromes (MDS). The first
question was if high-dose chemotherapy could induce polyclonal remission. Disease clonality
was investigated with karyotyping in patients with large chromosomal aberrations and
determination of X-chromosome inactivation patterns (XCIP) in female patients. These
investigations were performed at diagnosis and in clinical complete remission. The biological
background of non-random XCIPs in healthy female donors was investigated and improved
methods for determination of XCIPs were developed. A second question was the involvement
of the WT1 gene in MDS. This gene is highly expressed in acute myeloid leukemia (AML)
but not in normal bone marrow (BM). The involvement of WT1 in MDS was investigated by
looking at the expression patterns in various cell lineages in MDS bone marrow (BM).
Chapter 1 describes a study into the XCIPs of healthy females. The prevalence of XCIP
values in the healthy population follows a Gauss distribution, with a 50:50 ratio of inactivated
alleles being the most frequent. In a minority of cases the XCIP is skewed towards one of the
alleles (biological skewing). After our studies were planned an increased skewing of XCIP
was descibed in blood cells of healthy elderly females in up to 40% of cases, a process
described as acquired biological skewing. This clearly interferes with determination of
clonality based on XCIP in MDS patients, a disease most prevalent in elderly people. We
investigated whether the XCIP values in healthy elderly females were prone to fluctuations.
These fluctuations may result from a reduced number of stem cells and a flexible composition
of stem cells actively contributing to hematopoiesis at any given time point. If so, a
distinction could be made between acquired biological skewing and clonality based on these
fluctuations. For this purpose, XCIPs were determined at multiple time points in the blood
cells of 35 healthy donors, divided in three age groups, for a period of up to 18 months. No
fluctuations were found in any of the cell populations of any of the donors and we concluded
that acquired skewing cannot be distinguished from clonality by analyses at multiple time
points. The only exception was a fluctuation in the XCIP of the T cells of one donor, but as
the XCIP in the granulocytes and in the monocytes in this donor did not fluctuate, this T cell
fluctuation was probably due to a clonal expansion of T cells as the result of an infection. The
lack of fluctuations in XCIPs correlated nicely with two studies showing a major genetic
influence on the degree of skewing and the allele towards which the skewing occurred in
healthy twins, published near the completion of our time course study. An important
methodological finding was that pre-digestion of DNA with the restriction enzyme DdeI led
to a more reliable XCIP determination, most likely because it diminished differences in PCR
amplification efficiencies that exist between the inactivated and the active DNA.
Chapter 2 describes a newly developed positive control for the determination of XCIP by
PCR. All PCR based methods for determination of XCIP rely on the digestion of the DNA
with a methylation sensitive enzyme, such as HpaII. The inactivated allele, being heavily
methylated, will not be digested by the enzyme and will serve as the only available template
for subsequent PCR amplification. Critical in this procedure is complete digestion of non-
methylated DNA, because incomplete digestion results in falsely polyclonal XCIPs. Common
practice was to digest a male sample along with the digestion of female samples to monitor
the performance of the enzyme. However, this approach does not give information about the
digestion of individual samples. A quantitative, real-time PCR was designed to amplify a
gene escaping from X-chromosome inactivation (XE169). The digestion efficiency could be
measured in every sample, by quantifying the reduction of the XE169 gene after HpaII
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digestion. This method was tested in 30 blood samples from 2 donors and 28 MDS patients,
and paraffin embedded tissue from 2 patients with mantle cell lymphoma and 2 patients with
colon carcinoma. In two MDS cases a lack of XE169 reduction after digestion was identified,
leading to a falsely polyclonal XCIP. Inaccurate XCIP values were also found in three of the
paraffin embedded tissues due to inefficient digestion. We concluded that the described
method for monitoring digestion efficiency is both necessary and feasible for accurate XCIP
determination.
Chapter 3 describes the XCIP and cytogenetic findings of a large European study
investigating high-risk MDS patients at diagnosis and in clinical complete remission (CR).
The importance of cytogenetic analysis in CR was shown: a trend towards a shorter disease-
free survival was found for patients with a persisting cytogenetic aberration in CR compared
to patients whose cytogenetic aberration at diagnosis was no longer detectable in CR (p =
0.087). Furthermore, patients with a persisting cytogenetic aberration in CR showed a higher
relapse rate (p = 0.015). The XCIP determination at diagnosis showed 10% of patients with
less than 50% of clonal myeloid cells, though this did not impact the survival of these
patients. XCIP determination in CR showed no difference in survival of patients with or
without an XCIP response. This could partly be because of biological skewing, masking a
response to treatment in some patients (false non-responders) and partly because of the low
sensitivity of the technique; a fully balanced XCIP might be detected in a sample with up to
20% malignant cells (false responders).
Chapter 4 describes the expression pattern of the WT1 gene in different cell lineages in MDS
patients and healthy donors. Aberrant WT1 expression, detected with real-time RT PCR, was
found in the mature, CD34 negative BM cells in 12 of 13 MDS patients and two patients with
sAML (AML after MDS). No expression was detected in the CD34 negative cells of 6 healthy
donors. WT1 expression in primitive BM cells (CD34+, rhodamine dull) was not different
between MDS patients and donors. The aberrant WT1 expression could be pinpointed to the
erythroid precursor cells in a patient who was completely tranfusion dependent and in whose
BM dyserythropoiesis was observed. A second patient who was completely transfusion
dependent also had high WT1 expression in a CD34 negative cell fraction enriched for
erythroid cells. However, a third patient showed aberrant WT1 expression in a non-lymphoid,
non-erythroid CD34 negative BM fraction. This patient was not transfusion dependent. These
results indicated that aberrant WT1 expression is correlated with the abnormal maturation of
hematopoietic cells in MDS patients.
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Samenvatting
Dit proefschrift beschrijft moleculaire studies bij patiënten met het myelodysplastisch
syndroom (MDS). MDS is een kwaadaardige (maligne) ziekte van het beenmerg (BM). In
gezond BM verzorgt een beperkt aantal primitieve stamcellen voortdurend de vorming van
functionele bloedcellen. MDS ontstaat in eerste instantie als in het DNA van zo’n stamcel een
afwijking (mutatie) ontstaat, die leidt tot een groeivoordeel ten opzichte van de andere,
gezonde stamcellen. Zo ontstaat een groeiend aantal primitieve cellen met dezelfde mutatie
(klonale expansie). Opeenvolgende mutaties hebben tot gevolg dat deze cellen niet meer goed
kunnen uitrijpen. Dit leidt tot een ernstig tekort aan functionele cellen in het bloed. Tekorten
kunnen ontstaan aan bloedplaatjes (thrombopenie), granulocyten (neutropenie) of rode
bloedcellen (anemie). Ongeveer één derde van de patiënten overlijdt door complicaties
vanwege het tekort aan functionele cellen in het bloed. Bij ook een derde van de patiënten
wordt de opeenhoping van primitieve cellen in het BM in de loop van de tijd zo groot (>30%),
dat we spreken van acute myeloïde leukemie (AML). Het overige deel van de patiënten,
vooral ouderen, overlijdt aan andere oorzaken dan MDS. Een deel van de patiënten heeft een
slechtere levensverwachting en een grotere kans op leukemische ontaarding dan andere MDS
patiënten. Deze patiënten worden gekenmerkt door ernstige celtekorten in het bloed, een hoog
percentage primitieve cellen in het BM en bepaalde ongunstige afwijkingen in het DNA van
de BM cellen. Patiënten in deze groep leven zelden langer dan een jaar na het stellen van de
diagnose. De eerste vraag in ons onderzoek was of het mogelijk was om de normale,
polyklonale bloedvorming te herstellen in deze MDS patiënten door middel van intensieve
chemotherapie. De klonaliteit in BM cellen van MDS patiënten is op twee manieren
onderzocht. Ten eerste, door middel van klassiek chromosoomonderzoek (karyotypering) en
fluorescente in situ hybridisatie (FISH) in patiënten met grote chromosomale afwijkingen.
Vaak zijn de mutaties in het DNA van MDS cellen van zo’n aard dat grote stukken van
chromosomen en zelfs hele chromosomen zijn verdwenen (chromosomen 5 en 7), ook
bevatten MDS cellen vaak één of meerdere chromosomen te veel (chromosomen 8 en 3).
Deze mutaties zijn door middel van karyotypering en FISH onder de microscoop te bekijken.
Het verdwijnen van zo’n mutatie na behandeling duidt op het verdwijnen van de maligne
kloon. Ten tweede, door bepaling van het X-chromosoom inactivatie patroon (XCIP) in
vrouwelijke patiënten. Door de XCIP waarde te meten kan de hoeveelheid klonale cellen in
een celpopulatie bepaald worden. Vrouwen hebben in elke cel twee X-chromosomen waarvan
één van de vader en één van de moeder afkomstig is. Het XCIP ontstaat vroeg in de
ontwikkeling van het embryo, tijdens het stadium dat het embryo 32 tot 64 cellen telt. Eén van
de twee X-chromosomen in elke cel wordt dan geïnactiveerd. De kans op inactivatie is voor
beide X-chromosomen even groot. Het XCIP wordt tijdens volgende celdelingen onveranderd
doorgegeven. De XCIP waarde is de ratio tussen de geïnactiveerde allelen van het X-
chromosoom van de vader en de geïnactiveerde allelen van de moeder in een bepaalde
celpopulatie. Deze is meestal 50:50 in een normale, polyklonale celpopulatie. De XCIP
waarde is echter 100:0 of 0:100 in een maligne celpopulatie, waarin alle cellen afkomstig zijn
van dezelfde maligne kloon. Wij hebben ook onderzoek verricht naar klonaal lijkende XCIP
waardes bij gezonde vrouwen. Bovendien hebben wij de techniek om XCIP waardes te
bepalen verbeterd wat heeft geleid tot een meer betrouwbare methode.
De tweede vraag was hoe het WT1 gen betrokken is bij MDS. Het WT1 gen speelt een
cruciale rol vroeg in de vorming van de nieren, en in normale primitieve niercellen komt het
hoog tot expressie. Het WT1 gen komt ook hoog tot expressie in BM cellen van patiënten met
AML, maar niet in gezond BM, behalve in primitieve cellen. Inmiddels is duidelijk dat WT1
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ook een rol speelt vroeg in de normale bloedvorming. Welke rol precies is nog niet duidelijk.
Bovendien is het nog onduidelijk of afwijkende WT1 expressie een rol speelt bij het ontstaan
van leukemie en zo ja, welke rol. Het verband tussen WT1 expressie en MDS hebben wij
onderzocht door de WT1 expressie te meten in verschillende celtypen in het BM van MDS
patiënten.
Hoofdstuk één beschrijft een studie naar de XCIP waardes in gezonde vrouwen. De XCIP
waardes volgen een Gauss verdeling in de gezonde vrouwelijke bevolking: een gebalanceerde
ratio (50:50) komt het meest voor. Een verschuiving in de richting van één van de allelen
komt echter ook voor, dit noemt men biologische XCIP verschuiving. Kort na aanvang van
onze studie bleek uit een aantal publicaties dat de biologische XCIP verschuiving in het bloed
van gezonde vrouwen toeneemt met de leeftijd, dit noemt men verworven XCIP verschuiving.
Deze verworven XCIP verschuiving vormt een belangrijk obstakel bij het bepalen van
klonaliteit door middel van XCIP bepaling in MDS patiënten. Deze ziekte komt immers
voornamelijk bij ouderen voor. Wij hebben onderzocht of de XCIP verschuiving bij gezonde
vrouwen onderhevig is aan fluctuaties. Deze fluctuaties zouden het gevolg kunnen zijn van
een afnemende hoeveelheid bloedvormende stamcellen op oudere leeftijd in combinatie met
een voortdurend veranderende samenstelling van de actieve stamcellen binnen het gehele
stamcel compartiment. In MDS cellen komen deze fluctuaties niet voor omdat het verschoven
XCIP in deze cellen het gevolg is van een expansie van één maligne MDS kloon. Op deze
manier zou een onderscheid gemaakt kunnen worden tussen klonale bloedvorming als gevolg
van een maligne ziekte en een verworven XCIP verschuiving in gezonde vrouwen. Om dit te
onderzoeken zijn op meerdere tijdstippen de XCIP waardes bepaald in het bloed van 35
gezonde vrouwen, verdeeld in drie leeftijdscategorieën. In geen van de donoren is een
fluctuatie van het XCIP in de tijd waargenomen, gedurende een observatieperiode van
hoogstens 18 maanden. De enige uitzondering was een fluctuatie in het XCIP van de T-cellen
van één van de donoren. Maar aangezien andere bloedcellen (granulocyten en monocyten)
van dezelfde donor op dit tijdstip geen fluctuatie vertoonden, is het waarschijnlijk dat deze
fluctuatie het gevolg was van een klonale T-cel expansie, als gevolg van een infectie. Wij
concludeerden dan ook dat we het beoogde onderscheid tussen klonaliteit en verworven XCIP
verschuiving niet kunnen maken. Onze resultaten correleerden met de bevindingen van twee
studies die gepubliceerd werden tegen het einde van onze tijdreeks studie. Deze studies
concludeerden, op basis van onderzoek bij identieke tweelingen, dat zowel de mate als de
richting van verworven XCIP verschuiving in belangrijke mate bepaald worden door een
genetische factor. Deze genetische factor is nog niet geïdentificeerd, waarschijnlijk gaat het
om één of meerdere genen op het X-chromosoom die in verschillende vormen in de bevolking
voorkomen (polymorf). Als een vrouw verschillende vormen van zo’n gen van haar vader en
moeder heeft geërfd, dan zullen de cellen waar de ene vorm van het gen is geïnactiveerd een
groeinadeel ondervinden ten opzichte van de cellen waarin het andere chromosoom, en dus de
andere vorm van het gen, is geïnactiveerd. Dit leidt dan tot een toenemende verschuiving van
het XCIP naarmate er meer celdelingen hebben plaatsgevonden, dus met toenemende leeftijd.
Om de XCIP waarde te bepalen moet het chromosomale DNA eerst worden vermeerderd met
behulp van een polymerase ketting reactie (PCR). Een belangrijke technische bevinding in
onze studie was dat de efficiënties van PCR vermeerdering verschillend zijn voor het actieve
DNA en het geïnactiveerde DNA, dat grotendeels gemethyleerd is. Dit leidde in enkele
gevallen tot een onbetrouwbare XCIP waarde. Digestie van het chromosomale DNA met het
restrictie-enzym DdeI, voorafgaand aan de PCR, nivelleerde deze verschillen. Door de
digestie met DdeI wordt het DNA in grote stukken geknipt; deze stukken hebben een gelijke
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efficiëntie van PCR vermeerdering voor het actieve DNA en het geïnactiveerde DNA.
Hierdoor werd de bepaling van de XCIP waarde meer betrouwbaar.
Hoofdstuk twee beschrijft de ontwikkeling van een nieuwe positieve controle voor de XCIP
bepaling. Alle methoden voor XCIP bepaling die gebaseerd zijn op PCR, zijn afhankelijk van
volledige digestie van het DNA met een restrictie-enzym dat gevoelig is voor methylering,
zoals HpaII. Het geïnactiveerde allel van het X-chromosoom is in hoge mate gemethyleerd en
zal niet door HpaII worden gedigesteerd. Het blijft dus als enige allel over om te kunnen
worden vermeerderd door middel van PCR. Onvolledige digestie kan leiden tot een onecht
polyklonaal XCIP in een klonale cel populatie. Digestie van mannelijk DNA werd tot nog toe
gebruikt als controle op de werking van het enzym. Dit geeft echter geen informatie over de
mate van digestie in individuele monsters van vrouwelijk DNA. Wij hebben een kwantitatieve
PCR ontwikkeld op een gen (XE169) dat ontsnapt aan X-chromosoom inactivatie. Dit gen is
ongemethyleerd aanwezig op beide allelen van het X-chromosoom en H p a I I
herkenningsplaatsen in dit gen zullen dus volledig gedigesteerd worden. Door voor en na
HpaII digestie de hoeveelheid XE169 te meten in een monster, konden we de mate van
digestie uitdrukken als de mate van afname van het XE169 gen. Dit hebben wij getest in 30
bloed monsters van twee donoren en 28 MDS patiënten. Ook hebben we monsters getest van
twee patiënten met mantelcellymfoom en twee patiënten met coloncarcinoom. Deze monsters
waren maligne cellen die bewaard waren in paraffine (paraffine coupes). Een gebrek aan
XE169 afname na digestie leidde tot een onecht polyklonaal XCIP in twee monsters van MDS
patiënten. Ook in drie van de paraffine coupes veroorzaakte een inefficiënte HpaII digestie
een onjuiste XCIP waarde. Wij concludeerden dan ook dat de beschreven controle op HpaII
digestie zowel noodzakelijk als haalbaar is voor het identificeren van onechte polyklonaliteit
als gevolg van inefficiënte digestie.
Hoofdstuk drie beschrijft de bevindingen van een grote Europese studie naar MDS. Eén van
de doelstellingen was het bereiken van een normale, polyklonale bloedvorming op het
moment dat patiënten ziektevrij waren (complete remissie, CR), na intensieve chemotherapie.
De klonale aard van het BM en/of bloed van MDS patiënten is bij diagnose en tijdens CR
onderzocht door middel van karyotypering, FISH en XCIP bepaling. Wij hebben het belang
aangetoond van chromosoom analyse, door middel van karyotypering, tijdens CR. Patiënten
met een voortdurende chromosomale afwijking vertoonden een trend in de richting van een
kortere ziektevrije overleving, ten opzichte van patiënten bij wie de chromosomale afwijking,
aanwezig bij diagnose, niet meer aantoonbaar was tijdens CR (p = 0.087). Een terugkeer van
de ziekte kwam bovendien vaker voor bij patiënten met een voortdurende chromosomale
afwijking (p = 0.015). Uit XCIP bepalingen bleek dat van 10% van de patiënten het bloed
en/of BM minder dan 50% clonale myeloïde cellen bevatte, wat duidde op een meerderheid
van polyklonale cellen. Dit had echter geen invloed op de overleving van deze patiënten. Ook
het al dan niet bereiken van XCIP respons tijdens CR was niet van invloed op de ziektevrije
overleving. Dit kan enerzijds verklaard worden doordat in sommige patiënten een biologische
XCIP verschuiving de identificatie van een XCIP respons op behandeling in de weg stond
(onechte niet-responders), anderzijds is de techniek relatief ongevoelig. Dit kan ertoe leiden
dat een monster met een XCIP waarde van 50:50 nog 20% maligne cellen kan bevatten
(onechte responders).
Hoofdstuk vier beschrijft een studie naar de expressie van het WT1 gen in normale BM cellen
en BM cellen van MDS patiënten. De mate van WT1 RNA expressie werd bepaald door het
RNA eerst te vertalen in cDNA door middel van reverse transcriptase (RT). De hoeveelheid
WT1 in dit cDNA werd vervolgens bepaald door middel van kwantitatieve PCR.
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Verschillende celtypes in het BM werden van elkaar gescheiden door ze te sorteren op basis
van specifieke moleculen die op de celwand van de verschillende cellen voorkomen.
Afwijkende WT1 expressie werd aangetoond in rijpe BM cellen van 12 van de 13
onderzochte MDS patiënten en in twee patiënten met secundaire AML na MDS. WT1
expressie was niet aantoonbaar in de rijpe BM cellen van 6 gezonde donoren. WT1 expressie
was even hoog in primitieve BM cellen van MDS patiënten en donoren. Na verder sorteren
van BM cellen was de afwijkende WT1 expressie in één patiënt uitsluitend aantoonbaar in
voorlopercellen van de rode reeks. Deze patiënt was volledig afhankelijk van bloed
transfusies en de rode voorlopercellen in het BM vertoonden rijpingsstoornissen. In een
tweede patiënt was de afwijkende WT1 expressie ook uitsluitend aantoonbaar in een BM
celpopulatie met een hoog percentage rode voorlopercellen. Ook deze patiënt was volledig
afhankelijk van bloedtransfusies, wat duidt op een verstoorde uitrijping van rode bloedcellen.
In een derde patiënt was de afwijkende WT1 expressie echter uitsluitend aantoonbaar in een
celpopulatie waarin zich geen lymfocyten of rode bloedcellen bevonden. Waarschijnlijk
bevatte deze populatie een hoog percentage myeloïde cellen, cellen die ook vaak
rijpingsstoornissen vertonen in MDS. Deze patiënt was niet afhankelijk van bloedtransfusies.
Deze resultaten gaven aan dat er een correlatie bestaat tussen afwijkende WT1 expressie en de
verstoorde uitrijping van BM cellen in MDS patiënten.
In dit proefschrift hebben we een aantal studies uitgevoerd die meer licht werpen op de
ontstaanswijze van het myelodysplastisch syndroom. We hebben gebruik gemaakt van nieuwe
moleculaire technieken, hierin enige verbeteringen aangebracht en deze uitgetest in klinische
studies. Ons begrip van MDS neemt duidelijk toe dankzij de interactie tussen laboratorium en
kliniek, zoals in dit proefschrift is beschreven.
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Dankwoord
Vele mensen naast mij hebben hun best gedaan om van mijn promotie onderzoek een succes
te maken. Al deze mensen wil ik dan ook hartelijk bedanken. Een aantal wil ik met name
noemen. Ten eerste Theo, mijn promotor; al waren we het niet altijd eens over de te volgen
koers, met name wat betreft het WT1 werk, bedankt voor de fijne samenwerking en
uitwisseling van gedachten. Vooral in de laatste fase heb ik veel aan je gehad. Reinier, co-
promotor, altijd was je bereid mee te denken over hoe het verder moest. Hier heb ik veel aan
gehad, vooral wanneer zich echt moeilijke situaties voordeden. Ewald, eerste co-promotor,
vooral in het begin was je bij mijn project betrokken, als hoofd van het lab, maar
voornamelijk als initiatiefnemer van de kwantitatieve, of real-time PCR. Ook  was  het fijn
om aan het eind van de week met jou en anderen, onder het genot van een ‘CHL-biertje”, het
eens over andere dingen dan wetenschap te hebben. Joop, jij nam het stokje van Ewald over
toen je uit Rotterdam kwam om in Nijmegen hoofd van de moleculaire unit te worden.
Hoewel MDS niet jouw voornaamste interesse was heb je toch je uiterste best gedaan zodat
het lab- en schrijfwerk netjes afgerond kon worden. Dan de mensen op het lab: Ruth, in eerste
instantie hielp je me alleen met de CE analyses, maar in de loop van de tijd heb ik jouw
volledige labtijd voor mijn onderzoek kunnen claimen, iets wat zeker niet gelukt was als je
dat zelf ook niet gewild had. Heel erg bedankt voor alle gezelligheid en al het werk dat je voor
mijn onderzoek hebt verzet. Leonie, je kwam als stagiaire en eindigde als analiste. Je hebt een
behoorlijk deel van dit proefschrift bij elkaar gepipetteerd. Ik weet alleen nog steeds niet hoe
je het voor elkaar krijgt om CRIANT samples aan te voelen komen. Aswin, je kwam eigenlijk
net te laat voor mij. Ik had graag nog veel meer gebruik gemaakt va jouw kennis over WT1
dan ik nu heb kunnen doen. Succes met de voortzetting! Ook de overige mensen van de
moleculaire unit heel erg bedankt voor hulp en de goede werksfeer: Louis, die niet alleen
goed kan PCR-en maar ook biljarten, Evelyn, mijn buurmeisje op het lab, Liesbeth, Ellen,
Marion, Annet, Aniek, Piwi, Toon, Aldi, Jules, Laura, Jeroen, Bert, Gorica, Sake, Jurgen en
de vele studenten die voorbij gekomen zijn. Speciale dank verdienen ook de mensen van de
analytische ondersteuning, Arie, Gertie, Peter en Jan, zonder jullie expertise was het niets
geworden. Ook van de mensen van de BMT en de beenmergmorfologie heb ik regelmatig
hulp ingeroepen en gekregen, veel dank daarvoor. De overige mensen van het lab en de artsen
van de afdeling bloedziekten wil ik graag bedanken voor de vele momenten van
samenwerking. Eén iemand moet ik nog noemen: Robert Polenewen, jij bent één van de
vriendelijkste en meest hardwerkende mensen die ik ken, ik heb daar veel bewondering voor.
Ook buiten het werk ben ik een aantal mensen dank verschuldigd. Allereerst Dolly, jij hebt
het meest te lijden gehad van mijn chagrijnige buien als het schrijven niet goed ging. Bedankt
voor je steun, je liefde en je geduld. Gelukkig kon ik ontspanning vinden bij vrienden als
Richard & Leonie, Paul & Margriet, Michiel en gelukkig mijn ouders. Elke week trainen met
Richard, later met Zeban, en weer later met allebei, was en is absoluut noodzakelijk om de
spanningen niet te hoog op te laten lopen, net als het maken van muziek. Als drummer kan je
in je eentje niet veel muziek maken, veel dank dus aan iedereen met wie ik samen heb mogen
spelen: Jan, Paul, Jasper, Maarten en Freek, maar ook de heren van Montana Red Dog en de
Touch, en niet te vergeten Geert, oprichter van de mooiste oefenruimte in de omgeving van
Nijmegen (Red House).
Tot slot, aan iedereen die ik niet genoemd heb maar die wel zijn of haar bijdrage heeft
geleverd: ‘thank you baby!’.
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ALL’S WELL THAT ENDS WELL
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